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ABSTRACT:
Cancer is a devastating disease, affecting millions of individuals every year.
Though no cure exists for cancer at present, countless years of research have given rise to
promising treatments such as Trastuzumab, Taxol, Tamoxifen, VP-16 and cisplatin. The
majority of these treatments are non-selective thus affecting both normal and cancerous
cells. Pancratistatin, a natural compound obtained from the Hawaiian spider lily, is
known to be specific and selective in inducing apoptosis in multiple cancer cell lines
through selectively targeting the mitochondria. In this study it was discovered that PST
induced increased levels of cytosolic pro-apoptotic protein Bad in the cytoplasm as well
as localization of Bax to the mitochondrial membrane. Release of Cytochrome c due to
membrane permeabilization indicating the activation of the mitochondrial (intrinsic)
pathway of apoptosis was initiated.
Tamoxifen is a known anti-estrogen compound, which has the capability to
induce apoptosis in estrogen receptor dependent breast cancers selectively. This
compound is relatively non-toxic to normal cells. Recently, it was reported that
Tamoxifen has the capability of destabilizing mitochondrial membrane potential. In
combination with the anti-estrogen Tamoxifen, PST had a synergic effect in both
estrogen receptor positive as well as estrogen receptor negative cells at lower doses than
previously reported. Furthermore, whole cell reactive oxygen species levels were
increased and mitochondrial destabilization was observed. Thus the present work
provides evidence to support the observation that Tamoxifen might work through
mechanisms distinct from the canonical estrogen receptor antagonism and act
synergistically with PST.
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CHAPTER 1: INTRODUCTION

1.1 Cancer
Our bodies are immensely complicated machines made up of trillions of cells,
each cell containing billions of base pair DNA. This DNA codes for proteins which carry
out the roles necessary to maintain normal function and homeostasis within the cell.
Protein function is dictated by the structure, which is in turn governed by the genetic code
that serves as a blueprint for life. It is therefore mutations in a small group of critical
genes (oncogenes) that results in uninhibited cell growth which ultimately leads to tumor
development (Kliensmith 2006). The effects of the tumor as felt by the individual can be
categorized as invasive; in which the cancer affects surrounding tissue or metastastatic; in
that the tumor moves to other regions of the body (Kliensmith 2006). These factors lead
to interference of normal bodily functions and if left untreated may lead to death.

1.1.1 Cancer Statistics
Cancer is a disease which has continuously plagued societies for thousands of
years and even today it remains as one of the most frequently diagnosed and deadly
diseases despite exhaustive efforts in cancer research. In 2008 it was projected by the
Canadian Cancer Society that new cancer cases will reach 166,000 and cancer related
mortality will approach 73,000 in Canada alone (www.cancer.ca). The most common
types of cancers differ in males and females. In particular in males the most frequently
diagnosed form of cancers include: prostate (20,400 new cases), lung (11,900 new cases)
and colorectal (10,600 new cases). In Females the most highly diagnosed forms include:
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breast (19,300 new cases), lung (9,300 new cases) and colorectal (9,100 new cases)
(www.cancer.ca).

1.1.2 Causes of Cancer
Cancer is caused by a variety of factors including: diet, lifestyle, family health
history and exposure to industrial chemicals (Ames et. al. 1995). It is therefore adequate
to point out that cancer is not a disease with one cause; instead cancer is a heterogeneous
disease, which arises from a life-time accumulation of mutations in very specific regions
of DNA. This factor influences cancer cell development by causing mutations in the
DNA of genes critical to cell growth, cell cycle maintenance and apoptosis inducing
genes (tumor suppressor genes). Mutated versions of such genes are termed oncogenes.
Proto-oncogenes are normal genes responsible for inhibition of apoptosis and
propagation of cellular growth. When proto-oncogenes become mutated and become
oncogenes they resume normal function, however, they do not respond to inhibitory
stimuli leading to increased cell division, and inhibition to cell suicide stimulating factors
(Osborne et. al. 2004, Weinberg 1996). Tumor suppressor genes in normal cells induce
apoptosis when the conditions for growth are not met. These genes when mutated to
oncogenes lack the normal function and thus prevent the initiation of apoptosis in cancer
cells which contributes to cancer cell formation (Chabner, Roberts 2005, Weinberg
1996).
It has been found that lifestyle, environment and diet are immensely tied into
cancer cell development and is responsible for approximately 80% of all cancers cases
(Ames et. al.

1995). Compounds which reduce the body's capacity to dealing with
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oxidative stress increase the propensity of oxidative damage to cellular DNA. The most
common cause of such DNA mutation in cancer is smoking cigarettes. Tobacco products
consumed by individuals are responsible for one third of all cancer cases. The exact
mechanism of cancer cell development by these products is unknown, however it is
postulated that these compounds reduce the amount of natural anti-oxidents circulating
the body, thereby sensitizing individuals to oxidative stress induced DNA mutation
(Ameset. al. 1995).

1.2 Breast Cancer
Breast cancer is the most highly diagnosed carcinoma in women, new cases of
this disease are projected to reach 19,300 in 2008 (www.cancer.ca). For this reason it has
been one of the most fiercely researched forms of cancer. Due to such research efforts
great progress has been made in the understanding of this disease and its progression.

1.2.1 Breast Cancer Development
Breast cancer like all cancers is a genetically and clinically heterogeneous disease.
The specific causes of this disease have been significantly studied and it has been shown
to arise primarily as a result from the malignant transformation of mammary stem and/or
progenitor cells (LaMarca, Rosen 2008). Post natal mammary gland development is
coordinated by both systemic hormones and growth factors. In particular hormones such
as progesterone and estrogen drive the development of mammary tissue through the
actions of their respective receptors: progesterone receptor (PR) and estrogen receptor
(ER) respectively (LaMarca, Rosen 2008). However, up-regulation of the proto-oncogene
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estrogen receptor has been shown to increase the probability of breast tumor development
(Mense et. al.

2008). Furthermore specific genes have been found to have a high

frequency of mutation in breast cancer increasing the probability of disease development.
In particular, it has been found that mutations in tumor suppressor genes: p53 and
BRCA1 increases the propensity of breast cancer development (Gayther et. al. 1995).
Estrogen receptors (ER's) are members of the nuclear receptor superfamily
(NR's) and induce the pleiotropic effects of estrogen (Shao, Brown 2003). The effect of
the estrogen receptor plays a critical role in the physiology and developmental processes
of normal breast tissue by inducing expression of specific genes. At present two types of
estrogen receptors have been discovered ERa and ER(3 which have distinctly opposite
roles. Estrogen receptor a (ERa) plays a pivotal role in mammery cell development by
acting as a transcription factor of key genes responsible for growth such as transforming
growth factor receptor (TGF) and epidermal growth factor receptor (EGFR) (Mandlekar,
Kong 2001). Interestingly it was found that ERa is antagonistic to the functions of ER0
which primarily acts to suppress growth of the cell (Mandlekar, Kong 2001). Therefore
the growth of ERa positive breast cancers has been shown to be accelerated in presence
of estrogen (Mense et. al. 2008).
Mutation in genes responsible for programmed cell death has been linked to
breast cancer development. In particular, the tumor suppressor gene p53 has been shown
to be mutated in approximately 30-50% of all breast cancer cases (Haider et. al. 1994).
Normal p53 when activated is responsible for inhibition of cell cycle propagation and
initiation of cell suicide via apoptosis. However, in breast cancer cells this mechanism is
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inhibited by the lack of functioning p53 (mutated p53) and therefore genetic mutations
propagate into daughter cells potentially leading to tumorigenesis (Haider et. al. 1994).
Also, mutations in the tumor suppressor gene termed breast cancer susceptibility
gene 1 (BRCA1) have been shown to increase the incidents of developing breast cancer
(Gayther et. al. 1997). BRCA1 is a DNA damage response protein involved in DNA
repair caused by ionizing radiation (Hongtae, Junjie 2008). Mutations in this gene
therefore reduce the cells potential in DNA repair increasing incidence of further
mutations and tumor development. In particular, germ line mutations in BRGA1 gene
have been shown to occur in 80-90% of familial cases of breast cancer (Gayther et. al.
1995).

1.3 Apoptosis
The cell consists of complex biochemical machinery that is critical to the normal
homeostasis and survival of the organism as a whole. When a cell no longer suits the
need of the organism it undergoes a suicide program termed apoptosis. Apoptosis was
first discovered in 1972 by kerr et. al. who found that cell death processes can be
categorized into two distinct forms: necrosis and apoptosis.

1.3.1 Necrosis and Apoptosis
Necrosis can be defined as pathological, inappropriate and passive. It is brought
about by physical or chemical factors such as heat, pressure, injury and chemical damage
(Szabo et. al. 2005). The changes within the cell upon such stimuli are random and do not
exhibit any distinct pattern because they are not controlled by any internal biochemical
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mechanism. Instead they bring about random damage to the many different organelles
that are integrated within the cellular environment. Such damage causes inflammatory
responses within the organism through the facilitated action of immune cells like
macrophages (Haslett 1992).
Apoptosis by contrast to necrosis can be defined as a physiological, appropriate
and active process which simply acts to activate a complex biochemical pathway that acts
to initiate cell suicide and remove the damaged cell from the organism. Initiation of this
process can be activated by factors such as cellular receptors, DNA damage, growth
factor deprivation and cell cycle arrest (Hickey et. al. 2001).
Once initiated this process requires the input of energy in the form of ATP and the
activation of proteases named caspases to orderly deconstruct the cell into very distinct
and visible components. In general the process involves the ordered destruction of cells
and phosphatidyl serine flipping which acts to recruit phagocytes which exhibit noninflammatory responses (Pandey et. al. 2000, Green, Reed 1998). Due to this order,
distinct apoptotic features can be visualized under a light and fluorescent microscope
including: DNA fragmentation, phosphatidyl serine flipping, membrane blebbing and
mitochondrial membrane potential collapse (Duke et. al. 1996).
Two distinct pathways exist in which a particular stimulus can induce apoptosis.
The two pathways are termed intrinsic and extrinsic, however the ultimate effect of both
pathways is the depolarization of mitochondrial membrane potential leading to
permeabilization and the release of apoptogenic factors such as AIF, cytochrome C, and
SMAC Diablo.
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1.3.2 Extrinsic Pathway
Apoptosis can be initiated by a specific group of death receptors on the surface of
the cellular membrane termed TNF receptor (tumor necrosis factor). The TNF receptor
family includes Fas receptor, TNF and TRAIL (TNF related apoptosis inducing ligand)
(Degterev et. al. 2003). Apoptosis by the extrinsic method is initiated by ligands that bind
to the receptor and induce a conformational change on the receptor which induces
apoptotic events. One key event induced by ligand binding to "death receptors" is the
recruitment of key proteins which form a death induced signaling complex (DISC)
(Ashkenzai, Dixit 1998). Once formed, the DISC complex acts to activate caspase-8
through cleavage of the zymogen procaspase-8 (figure 1-1). Caspase-8 then processes
Bid to truncated Bid (tBid) which in turn acts to destabilize the mitochondrial membrane
which releases apoptogenic factors that cause activation of caspase-3 (Ashkenzai, Dixit
1998). Therefore, Bid activation into tBid links the extrinsic pathway of apoptosis to that
of the intrinsic pathway (Chou et. al. 1999, McDonnell et. al. 1999, Korsmeyer et. al.
2000).
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Figure 1-1: The Extrinsic Pathway of Apoptosis

,'Ligand

Figure 1-1: The extrinsic pathway of apoptosis
In the extrinsic pathway of apoptosis, the death receptors are activated by ligand binding, which leads to the
formation of DISC (death inducing signaling complex) and the activation of caspase-8. Active caspase-8
causes the activation of caspase-3 and the formation of tBid, both of which lead to apoptosis.
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1.3.3 Intrinsic Pathway
Intrinsic pathway begins with cellular stress induced internally such as DNA
damage induced by DNA damaging agents such as: radiation, chemotherapies and
reactive oxygen species (Kroemer, Reed 2000). The intrinsic process of apoptosis is
centered on destabilization of mitochondrial membrane potential by pro-apoptotic
proteins.
When a DNA damaging agent is presented to a cell, the general intrinsic pathway
which is followed includes activation of p53 transcription factor, which up-regulates proapoptotic proteins including Bax. Bax, when activated, will localize to the outer
mitochondrial membrane and induce mitochondrial destabilization. Bax can induce
destabilization directly or indirectly. Direct mitochondrial pore formation through Bax is
thought to occur by Bax homodimerization (figure l-3a). Indirect Bax induced
mitochondrial pore formation is believed to occur mainly through the interaction with the
PTP (protein transition pore) complex on the outer mitochondrial membrane (figure 13b). Bax binding to the PTP induces opening of the PTP (Reed 2000). Depolarization of
mitochondrial membrane potential leads to the release of apoptogenic factors such as
cytochrome c, SMAC Diablo and AIF (Green and Reed 1998).
Cytochrome c, once released from the mitochondria, forms an ATP dependent
complex with APAF-1 (apoptosis activating factor-1) and caspase-9 termed the
apoptosome (Ashkenazi, Dixit 1998). The apoptosome then serves the role of inducing
activation of caspase-3 through cleavage of a zymogen procaspase-3 (figure 1-2).
Caspase-3 is an enzyme which is a part of a broad family of enzymes termed aspartyl
specifc cystienyl protease, which act via proteolysis through the cleavage of specific
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recognition amino acid sequence (DEVD). Caspase-3 translocates to the nucleus when
activated and targets key proteins for proteolysis such as ICAD (inhibitor of caspaseactivated DNase), once activated ICAD acts to cleave DNA in an ATP dependent manner
and causes chromatin condensation (Li et. al. 1997).
Smac/DIABLO (direct IAP binding protein with low pi) was found to be released
from the mitochondrial membrane along with cytochrom C (Verhagen et. al. 2000). This
protein was found to promote apoptosis by binding to and inhibiting IAP (inhibitor of
apoptosis protein). IAP acts to inhibit caspases necessary to propagate the apoptotic
signal cascade (Verhagen et. al. 2000).
It was observed that a key apoptogenic factor exists which can bypass the caspase
cascade all together and directly induce the effects of caspases. Apoptosis inducing factor
(AIF) was found to translocate to the nucleus once released from the mitochondrial
membrane and induce chromatin condensation and DNA degradation (Susin et. al.
1999).
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Figure 1-2: The Intrinsic Pathway of Apoptosis
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Figure 1-2: The intrinsic pathway of apoptosis, outer mitochondrial membrane permeablization by proapoptotic proteins (tBid, Bax, Bok) leads to the release of cytochrome c forming the apoptosome and
activating caspase-9, leading to caspase-3 activation. Simultaneously, AIF are released and trans-locates to
the nucleus, where it induces DNA fragmentation. As well, Smac/Diablo is released which inhibits
inhibitors of apoptosis proteins leading to prolonged caspase activation.
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1.4 Pro/Anti-apoptotic Proteins
Bcl-2 is a family of pro and anti-apoptotic proteins which contain homologous
domains; these domains are termed Bcl-2 homologous domains (BH domains) which
range from BH1-BH4 (Hunter et. al. 1996, Chinnadurai, Lutz 1995). Interaction of
pro/anti-apoptotic proteins involved in apoptotic regulation mainly involves the BH
domain. Currently, there are approximately 15 known pro/anti-apoptotic proteins. Bcl-2 family members share one or more Bcl-2 homologous (BH) domain and are divided into
two main groups according to whether they promote (pro-apoptotic) or inhibit (antiapoptotic) apoptosis. The pro-apoptotic family members are further classified according
to whether they contain multiple BH domains or BH3 only. The BH3-only proteins are
pro-apoptotic and require the co-operation of their multidomain relatives to induce
apoptosis (Kuwana, Newmeyer 2003).
Anti-apoptotic proteins include: Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and Al. These
proteins act to protect the cell mitochondria against permeabilization by sequestration of
pro-apoptotic proteins. All anti-apoptotic proteins contain some variation of BH1 and
BH2 domain, however the proteins Bcl-2 and Bcl-xl contain all four (BH1-BH4)
conserved domains (Levine et. al. 2008). The protein Bcl-2 acts to protect the
mitochondria by binding to Bax and forming Bax/Bcl-2 heterodimers inhibiting the
localization of Bax to the mitochondria and subsequently protecting against
permeabilization of the outer mitochondrial membrane (Goping et. al. 1998). Also, antiapoptotic proteins such as Bcl-2 and Bcl-xl reside on the outer mitochondrial surface
inhibiting mitochondrial membrane potential collapse caused by the pro-apoptotic
proteins Bax and Bak (Levine et. al. 2008).
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Pro-apoptotic proteins containing BH1-BH3 domains include: Bax, Bak and Bok.
Bax and Bak have the ability to destabilize the mitochondrial membrane directly. Work
by Wolter et. al 1997 showed that localization of GFP fused Bax from the cytosol to
mitochondria is a crucial event during apoptosis leading to mitochondrial destabilization.
Investigations by Kuwana et. al. 2002 showed that Bax in presence of Bid has the ability
to form pores on the mitochondrial membrane directly, thus allowing the release of
apoptogenic factors from the inter-mitochondrial membrane space. Furthermore, work by
Shimizu et. al. 1999 suggests that Bax and Bak have the ability to interact with voltage
dependent anionic channels (VDAC) on the mitochondrial membrane and thus
permeabilize the mitochondrial membrane allowing molecules such as Cytochrome c to
be released (figure l-3b).
Other pro-apoptotic proteins contain only BH3 domain and are comprised of only
alpha helix structure with no mitochondrial membrane binding domain, these include:
Bad, Bid, Bik, Rk, BNIP3 and BimL (Kuwana Newmeyer 2003). BH3 only proteins are
believed to play two distinct roles which are: localize pro-apoptotic proteins from
cytosolic compartments to the mitochondrial membrane (Bid) and sequestering antiapoptotic proteins (Bad) (Levine et. al. 2008). The BH3 only peptides Bid and Bim
activate Bax and Bak directly, whereas the Bad and Bik BH3 peptides act indirectly by
inactivating Bcl-xL or Bcl-2, thus allowing Bax and Bak to act unopposed (Kuwana
Newmeyer 2003). Therefore the pro-apoptotic mechanism primarily involves the
destabilization of the mitochondrial membrane.
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1.5 Mitochondria
Mitochondria play an integral role in energy metabolism through oxidative
phosphorylation, which generates energy in the form of ATP that is essential for the
various biochemical reactions inside a cell (Leist et. al. 1997). Energy metabolism in the
mitochondria involves reduction of O2 into H2O by electron transfer mechanisms through
redox reaction in the electron transport chain. There are many internal factors within the
mitochondria which when released activate the cellular processes involved in the
induction of apoptosis. Therefore, mitochondria play a central role in both the intrinsic
and extrinsic apoptotic pathways. The key outcome of both processes is induction of
mitochondrial membrane collapse and release of the key mitochondrial apoptogenic
factors such as Cytochrome c, AIF, and Smac/DIABLO (Green, Kroemer 2004, Yuan et.
al. 2001 Kroemer, Reed 2000, Zoratti, Szabol997).
As described earlier the release of the apoptogenic factors within the
mitochondria is guided by one of two potential mechanism that lead to mitochondrial
membrane potential (MMP) collapse. The first is by direct pore formation though the
localization of pore forming pro-apoptotic proteins such as Bax and Bak (figure l-3a)
(Green, Kroemer 2004) and the second is by opening of the mitochondrial protein
transition pore complex.
The opening of mitochondrial permeability transition pore complex (MPTP) is a
crucial event in apoptosis. This complex includes the voltage dependent anionic channels
(VDAC) which detects a change in mitochondrial membrane potential (A^m) and thus
opens the MPTP complex allowing molecules of up to 5000 Daltons to pass through
(Harris, Thompson 2000, Zoratti, Szabo 1997). Other integral components of the MPTP
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include adenine nucleotide transporter (ANT), benzodiazepine receptor, hexokinase (HK)
and cyclophillin D (figure l-3b). The MPTP complex can be opened directly through
interaction with pro-apoptotic proteins such as Bax, partial failure of electron transport
chain, cellular increases in reactive oxygen species and increases in the intra Ca
concentrations (Zoratti, Szabo 1997).
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Figure l-3a: Bax/Bak Mediated Mitochondrial Membrane Permeabilization
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Figure l-3a: Bax/Bak mediated mitochondrial membrane permeabilization. Upon induction of
apoptotic pathway, Bax and Bak migrate to the outer mitochondrial membrane where they homodimerize
and form pores. This pore leads to the release of Cytochrome c, as well as other apoptogenic factors
(Smac/DIABLO, AIF).

Figure l-3b: Opening of the Permeability Transition Pore Complex Mediating
Mitochondrial Membrane Permeabilization
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Figure 1 -3b: Opening of the permeability transition pore complex mediating mitochondrial
membrane permeabilization. Upon induction of apoptotic pathway, BAX interacts with VDAC on the
PTP where it leads to the opening of the PTP complex. Rapid in flow of H 2 0 and ions leads to swelling of
the mitochondrial matrix and rupture of the outer mitochondrial membrane releaseing apoptogenic factors
such as cytochrome C, AIF and Smac/DIABLO.
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1.5.1 Mitochondria in Cancer Therapy
Cancer cells have devised mechanisms that inhibit mitochondrial dysfunction and
prolong life of the cell in presence of various stresses. Recent advances in cancer research
have uncovered key differences between cancer and normal cell mitochondria such as:
mitochondrial membrane potential, metabolism, mitochondrial DNA mutations and
mitochondrial integrity due to rapid cell division. It is therefore possible to exploit these
key differences in cancer cell mitochondria to induce apoptosis in cancer cells
selectively.
A key difference in cancer cell metabolism over that of normal cells is the use of
anaerobic metabolism as opposed to aerobic metabolism (Modica-Napolitano, Singh
2002). This phenomenon has been named the "Warburg phenomena" where the reliance
on anaerobic metabolism aids in the protection of cancer cells from mitochondrial
induced apoptosis by reducing the risk of reactive oxygen species induced opening of the
MPTP complex (Green, Kroemer 2004). Despite this phenomena, it has been observed
that cancer cells have an increase in mitochondrial membrane potential (AYm) (ModicaNapolitano, Singh 2002, 2004) as observed by localization of the cell membrane
permeable cationic dye Rhl23. Experiments show that this dye accumulates in the
mitochondria of cancers including: kidney, ovary, pancreas, lung, adrenal cortex, skin,
breast, prostate, cervix, vulva, colon, liver and testis in greater extent then the normal cell
counterparts (Don, Hogg 2004). The hydrophobic nature of the compound is believed to
affect electron transport chain and ATP synthesis causing mitochondrial dysfunction.
This result indicates that the increase in mitochondrial membrane potential in cancer cells
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is driving the accumulation of the molecule into the mitochondria and also causing toxic
effects specifically in cancer cells (Don, Hogg 2004).
Mitochondrial DNA accounts for only 1% of expressed DNA inside a cell.
However the expression of genes from mitochondrial transcript DNA (mtDNA) is
imperative for normal cellular function (Modica-Napolitano, Singh 2004). Unlike
mammalian DNA, mtDNA has no introns, and no protective histones. Furthermore,
mtDNA is continuously exposed to oxidative stress due to oxidative phosphorylation
reactions. Work by Selvanayagam et. al. 2004 revealed that mutations in mtDNA of
NADH dehydrogenase subunit III is a phenotype associated with renal cell carcinoma.
Rapid cell cycle progression due to over-expression of genes responsible for
cellular growth is a phenomenon commonly observed in cancer cells. Due to this
occurrence, additional mitochondrial differences have been observed in cancer cells when
compared to normal cell mitochondria. It was recently postulated that cancer cell
mitochondria are unable to properly ensure proper formation of mitochondrial membrane
components during mitosis (Modica-Napolitano, Singh 2002, 2004). This lack of proper
mitochondrial replication during mitosis has the potential to cause the development of
mitochondria with altered inner and outer mitochondrial membrane compositions (Villa,
Doglia-2004).
These differences between cancer and normal cell mitochondria have the potential
to give rise to novel targets for chemotherapeutics research. A new class of compounds
termed "mitocans" has been proposed which have the ability to exploit the vulnerability
of cancer cell mitochondria (Neuzil et. al. 2007). Vitamin E analogues have recently
shown promise to target cancer cell mitochondria. One such compound which shows
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selectivity in inducing apoptosis through mitochondrial destabilization in cancer cells at
concentrations that is tolerated by normal cells is the vitamin E analogue a-tocopheryl
succinate (Neuzil et. al. 2007). Another compound, lonidamine, has been shown to cause
opening of the mitochondrial transition pore complex through binding to the adnenine
nucleotide transporter site (Neuzil et. al. 2007). Therefore the mitochondria can provide
novel targets for selective apoptosis induction (Kroemer 2003).

1.6 Current Chemotherapy Options
Current cancer treatment strategies depend on the severity of the disease. Upon
diagnosis of cancer, the treatment methods available include systemic and local
intervention. New techniques and compounds have lead to prolonged life and sometimes
complete inhibition of cancer re-occurrence. Unfortunately no cure exists and drugs used
as chemotherapies can have drastic side effects which in turn have the potential to do
more harm then good to the patient.
Local therapies include surgical intervention and ionizing radiation (IR). Removal
of the cancerous growth is accomplished by surgical intervention along with
supplemental drugs to prevent reoccurrence of the disease. Radiation therapy is given to
approximately 70% of cancer patients (Martin 2001). This treatment involves inducing
oxidative stress leading to DNA damage on cancerous tissue through focused beams of
ionizing radiation (Jeremic 2004). Unfortunately the ionizing beam of radiation also
affects nearby normal cells, increasing the probability of DNA damage in normal tissue
potentially leading to formation of secondary tumors (Zhang et. al. 2001).
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Nearly 50% of all newly diagnosed cancer patients will receive some form of
systemic chemotherapy (Martin 2001). Systemic therapies vary in the way that they
target a particular cancer cell however the overall desired effect of these therapies
remains the inhibition of growth and the induction of apoptosis. These therapies work
simply by the fact that cancer cells divide rapidly and therefore are more vulnerable to
stresses that are imposed to replication machineries. Specific targets of systemic therapies
include: cell surface receptors, hormonal receptors, DNA, and cell cycle machinery.

Immunotherapy's act on specific protein targets on the cancer cell membrane.
They induce immunological responses and activate internal cellular processes that lead to
apoptosis. This type of chemotherapeutic strategy is used in the treatment of breast and
leukemic cancers (Kim 2005). One such immunotherapy named Trastuzumab is a
monoclonal antibody therapy which targets breast cancers that expresses HER-2 which is
an epidermal growth factor responsible for cellular growth (Duffy 2005). Once bounded
to HER-2 Trasuzumab causes down modulation of HER-2 leading to: cell cycle arrest
through p27, immune response, and inhibition of angiogenesis (Duffy

2005).

Unfortunately, treatment with Trasuzumab is limited to cancers expressing HER-2 and
current research indicates that even when HER-2 expression is high the effect of
Trasuzumab is limited to the duration of therapy (Albanell, Baselga 2001).
Hormonal therapies include a class of drugs termed Selective Receptor
Modulators (SRM's). These compounds are selective for certain types of breast, ovarian
and thyroid cancers which exhibit specific cellular receptors (Kleinsmith 2006).
Tamoxifen is the prototypic SRM, which acts antagonistically on the estrogen receptor
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(Smith et. al. 2004). Estrogen receptor as previously mentioned is a transcription factor
involved in expressing proteins critical for maintaining cell growth and survival (Shao,
Brown 2003). Therefore the antagonistic effect of Tamoxifen acts by sequestering the
estrogen receptor so that it cannot bind to estrogen and therefore cutting off vital receptor
mediated growth mechanisms. The benefit of this therapy is that it is selective only
towards cells that exhibit estrogen receptor and therefore has little toxic effects towards
normal cells. However, the downside is that it is limited to cancers expressing the
estrogen receptor.
Cell cycle inhibitory drugs act by reducing the rate of mitosis thereby leading to
apoptosis. The class of drugs called Taxanes, isolated from the pacific yew tree, works in
such a way. In particular, one such compound called Taxol, acts to induce apoptosis by
microtubule stabilization during mitosis. Taxol binds to pockets in P-Tubulin inhibiting
GTP hydrolysis of the other side of the polymer (Yeung et. al. 1999). Inhibition of
microtubule depolymerization in G2-M phase leads to bcl-2 phosphorylation which
inhibits bcl-2's normal anti-apoptotic activity, therefore leading to apoptosis (Yeung et.
al. 1999). Unfortunately, taxol is non-specific and exhibits toxicity to normal cells
leading to drastic side-effects to the patient. For this reason selective targeting of cancer
cells is a priority in novel therapeutic strategies in cancer therapy research.

1.7 Pancratistatin and Tamoxifen
The vast amount of research in cancer therapeutics has given rise to many
compounds which target many biochemical processes in cancer cells. All the research in
such compounds have made great strides in therapeutic options to patients, however the
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limitations of each individual treatment remains with respect to unwanted and drastic side
effects. Therefore, the current focus is in the development of compounds which are toxic
and selective towards cancer cells.
Previous investigations with Tamoxifen (figure l-4a) have established the
antagonistic action of this drug on the estrogen receptor. Current advances in Tamoxifen
research have shown that it plays roles outside the normal estrogen receptor antagonism,
which induces apoptosis in ER+ cancer cells. Tamoxifen induced apoptosis involves
biochemical pathways involving: Protein kinase C induced apoptosis, binding to
calmodulin, induction of c-Myc, mitogen activated protein kinases (MAPK) and
mitochondrial dysfunction (Mandlekar, Kong 2001). In particular, work by Moreire et. al.
2006, has shown that Tamoxifen has binding affinity to complex 1 of the electron
transport chain, which in turn causes destabilization of mitochondrial membrane potential
and increases levels of reactive oxygen species. Also, work done by Kallio et. al. 2005,
showed that MCF-7 (mammary adenocarcinoma) cells treated with 5-7uM Tamoxifen in
serum free media exhibited mitochondrial dysfunction, reactive oxygen species increases
and Cytochrome c release.
There is a clear link between consumption of natural compounds and decreased
susceptibility to disease. Epidemiological research has proven that consumption of
phytochemicals from fruits and vegetables results in reduced risk of cancer development
over the lifetime of an individual (Reedy et. al. 1997). Therefore, isolating natural
substances which show promise as anti-cancer compounds, is an approach used by many
researchers and has thus opened the window to current chemotherapeutics (taxol) and
future promising compounds (pancratistatin).
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Pancratistatin (figurel-4b) is a natural compound that was originally isolated
from the spider lily Pancratium Litorale in 1993 by Pettit et. al. Early work with PST
revealed the potential to act as an anti-neoplastic and anti-fungal agent (Luduena et. al.
1992). Pharmacological work with PST has been limited due to the low yield obtained
from extraction of this compound from the spider-lily, therefore, surprisingly little in-vivo
and in-vitro work has been completed in PST related research. Previous results from our
lab demonstrated the ability of PST to induce apoptosis in cancer cells (McLachlan et. al.
2005). Importantly, the effects of PST induced apoptosis were found to be selective
towards cancer cells and having no toxic effects towards normal cell lines. (McLachlan
et. al. 2005). The exact biochemical mechanism of action in PST induced apoptosis is
unknown, however recent advances in our lab demonstrate that this drug has potential
targets existing directly on the mitochondria of cancer cells leading to selective induction
of apoptosis. Therefore, research is currently being undertaken in our lab to exploit this
feature of cancer selectivity, and understand the mechanism of how this phenomenon
occurs.
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Figure l-4a: Chemical Structure Tamoxifen Citrate
N-

O.

^J

• C6H807

c=c.V

K^
Figure 1 -4a: Chemical structure of tamoxifen citrate
Tamoxifen citrate (C32H37NO8) has a molecular weight of 563.32g/mol. The molecular structure is shown
here

Figure l-4b: Chemical Structure of Pancratistatin
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Figure l-4b: Chemical structure of pancratistatin
Pancratistatin (C14Hi5NOg) has a molecular weight of 325.28g/mol. The molecular structure is shown here.
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1.8 Objectives
The present study expands upon the previous work completed on PST which
established this compound as a selective inducer in apoptosis by targeting the
mitochondria. The objectives of this investigation include:

1. Study combinatorial treatment of cancer cells with PST and Tamoxifen in both ER
negative and ER positive breast cancer cells as well as determine the level of toxicity to
normal cells in-vitro.

2. Investigate biochemical features in PST induced apoptosis in both Hs578-T and MCF7 cell lines in order to gain key insights into the biochemical mechanism induced by PST
treatment.

3. Establish a mouse breast cancer model in order to investigate the in-vivo response of
PST and Tamoxifen treatment.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Cell Culture
2.1.1 Cell lines
Normal human fibroblast (NHF) cells (AG09309) were obtained from Coriell
Institute for Medical Research, Camden, NJ, USA. Mammary gland adenocarcinoma
(MCF-7) cells were obtained as a gift from Dr. Hubberstey and Dr. Porter, University of
Windsor as well as purchased from American Type Culture Collection (ATCC).
Mammary gland carcinoma (Hs-578T) cells were obtained from the American Type
Culture Collection (ATCC), Manassas, VA, USA.

2.1.2 Media and Supplements
Dulbecco's modified Eagle's medium (DMEM) / nutrient mixture Ham's F-12
medium modified with 2 mM L-glutamine obtained from Sigma Chemical Company,
Mississauga, Ontario, Canada.

L-Glutamine and Gentamycin were purchased from

Invitrogen Canada Inc., Burlington, Ontario, Canada. Fetal bovine serum (FBS), glucose,
bovine insulin, sodium bicarbonate and sodium pyruvate were purchased from Sigma
Chemical Company, Mississauga, Ontario, Canada.

2.2 Pancratistatin and Tamoxifen
Pancratistatin (PST) was obtained from our collaborator, Dr. James McNulty,
McMaster University, Hamilton, Ontario, Canada. PST was isolated from the bulb of the
Hymenocallis littoralis, a spider lily native to the islands of Hawaii, following a previously
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published method (Pettit et al. 1993). Tamoxifen Citrate was purchased from Sigma Chemical
Company, Mississauga, Ontario, Canada.

2.3 Antibodies
Monoclonal primary antibodies raised in mouse were purchased from Sigma Chemical
Company, Mississauga, Ontario, Canada these consisted of: anti-Bax, anti-Bcl-xl and anti-Bcl-2.
Polyclonal primary antibodies raised in rabbit were purchased from Sigma Chemical Company,
Mississauga, Ontario, Canada and consisted of: anti-Actin and anti-Bad. Furthermore polyclonal
primary raised in rabbit anti-Succinate Dehydrogenase B and monoclonal primary raised in
mouse anti-Cytochrome c antibodies were purchased from Santa-Cruz Biotechnology Inc., SantaCruz, CA. Secondary anti-rabbit and secondary anti-mouse conjugated antibodies to HRP were
purchased from Sigma Chemical Company, Mississauga, Ontario, Canada.
2.4 Apparatus and Instrumentation
The Leica DM IRB fluorescent microscope was obtained from Lieca, Wetziar
Germany. The multi-well plate reader, Spectra Max Gemini XS, was obtained from
Molecular Devices, Sunnyvale, California and the UV-Visible Spectrophotometer was
purchased from Thermo Technologies. Chemi-Imager v5.5 (Alphatech Inovations) was
used to visualize westernblots. A Becton Dickinson FACSCalibur flow cytometer was
used at Wayne State University.
Cell culture was conducted under sterile conditions in a class-II type A/B3
Biosafety cabinet (NuAire Inc., Plymouth, MN, USA), and all cultures were maintained
in a CO2 incubator containing a HEPA filter (Thermo Forma Scientific, Inc, Marietta,
OH, USA)
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Centrifugation was conducted using a low speed Jouan CR3-I centrifuge (Jouan by
Thermo Electron Corporation, Waltham, MA, USA) and a MC2 DESAGA centrifuge
(Sarstedt-Gruppe, Montreal, Quebec). Other general laboratory equipment included the
following: a pH Meter (VWR, Model 8100) with buffer solutions from VWR, Adventurer
balance (OHAUS, Ontario, Canada), Vortex Jr. Mixer from Scientific Industries Inc, 1296-002
DELFIA plate shaker from Wallac, Rocking platform model 200 from VWR, and Corning
stirrer from Fisher Scientific.

Additionally, a Dounce homogenizer from Kontes Glass

Company (NJ, USA), freezer vials (VWR), and Eppendorf pipettes (Fisher Scientific) were
used.

2.5 In-vitro Proliferation of Cell Lines
MCF-7 cells were grown at 37°C and 5% C0 2 in DMEM / Nutrient Mixture
Ham's F-12 medium modified to contain 2mM L-glutamine, 1.5g/L sodium bicarbonate,
and lOmg/mL Gentamycin supplemented with 10% fetal bovine serum (FBS).
NHF cells were grown at 37°C and 5% C0 2 in DMEM modified to contain 2mM
L-glutamine, 1.5g/L sodium bicarbonate and lOmg/L Gentamycin supplemented with
15% FBS, IX essential and IX non-essential amino acids, and IX vitamins.
Hs578-T cells were grown at 37°C and 5% C0 2 in DMEM with 4 mM Lglutamine adjusted to contain 1.5g/L sodium bicarbonate, lOmg/L Gentamycin, and
4.5g/L glucose supplemented with O.Olmg/mL bovine insulin and 10% fetal bovine
serum
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2.6 Sub-culturing of Cells
Cells were sub-cultured by removing the culture medium by aspiration and
rinsing the cells with a 0.25% (w/v) trypsin - 0.53mM EDTA solution or Puck's solution
(140mM NaCl, 5mM KC1, 5.5mM glucose, 4mM NaHC0 3 , 0.8mM ethylenediamine
tetraacetic acid (EDTA)) in order to remove all traces of serum (serum contains a trypsin
inhibitor). Additional 20% (w/v) trypsin solution was added and the cells were incubated
at 37°C until the cell layer began to disperse (usually within 5 to 10 minutes). Additional
appropriate complete media was added, cells were aspirated, and appropriate aliquots of
the cell suspension were added to new culture flasks or plates.

2.7 Treatment of Cells with Anti-Cancer Drugs: PST and Tamoxifen
Cells were grown to 70% confluence and treated with the indicated concentration of
Pancratistatin (PST) and Tamoxifen by the addition directly to fresh complete medium for
varying time periods.

2.8 Data Collection and Analysis
All fluorescent and phase contrast pictures were taken using Improvision's OpenLab
3.1.5 Software on a Leica DM IRB fluorescent microscope. All pictures were processed using
Adobe Photoshop software and Microsoft Powerpoint software. Fluorescence measurements
were collected using SoftMax PRO 3.1.2 software and a SpectraMax Gemini XS fluorescent
plate reader. Microsoft Excel software was used for data representation and statistical analysis.

29

2.9 Nuclear Staining and Phase Microscopy
In order to examine nuclear morphological changes induced by treatment of PST
and Tamoxifen, cancerous and non-cancerous cells were grown and treated with PST and
Tamoxifen, followed by staining with lOuM of Hoechst-33342 (Sigma Chemical
Company, Mississauga, Ontario, Canada). The fluorescent dye was directly added to the
culture media at a final concentration of luM and incubated for 10 minutes. Cells were
examined under a fluorescent microscope and phase contrast and fluorescence pictures
were taken.

2.10 Trypan Blue Staining
The Trypan blue exclusion test (Sigma Chemical Company, Mississauga, Ontario,
Canada) is a common method to measure the number of viable cells in a given sample.
Cells were trypsinized as previously described, except that floating cells were spun down
and added to the cell suspension. Fresh media was added and lOuL of the cell suspension
was added to lOuL of 0.4% Trypan blue stain.

Cells were counted using a

hemacytometer and the number of cells per volume unit of sample was calculated.

2.11 Flow Cytometry Analysis
Flow cytometry was carried out at Wayne State University by a trained specialist
(Dr. Kim Zukowski). A Becton Dickinson FACSCalibur equipped with two lasers: a
standard Argon laser at 488 nm and a red diode laser at 635 run which measures forward
scatter (cell size) and side scatter (granularity, complexity). The FACSCalibur is
controlled by a FACStation which consists of a Macintosh Power PC 7600 loaded with
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Becton Dickinson Immunocytometry Systems acquisition and analysis software including
CellQuest, ModFit, FACSComp, FACSConvert, Attractors, and Paint-A-Gate. Cells were
analyzed for annexin binding and tunnel labeling.

2.11.1 Annexin-V Binding Assay
The cells were grown and treated with varying combination of drugs (PST and
Tamoxifen). After various treatment times, an annexin-V binding assay (Sigma Chemical
Company, Mississauga, Ontario, Canada) was conducted using a purchased kit and the
manufacturer's protocol. Cells were harvested via trypsinization, washed twice using
phosphate buffer saline (PBS) (0.137mM NaCl, 2.7mM KC1, 8.0mM Na 2 HP0 4 , 1.47mM
KF^PCv) and then re-suspended in annexin-V binding buffer (lOmM HEPES and NaOH
pH 7.5, 140mM NaCl, 2.5mM CaCl2) at a concentration of -10 6 cells/mL.

IOOUL

of

each solution was transferred to eppendorf tubes, 5uL of annexin-V-FITC conjugate was
added, and the mixture was incubated for 15 minutes at room temperature.

After

incubation, the cells were re-suspended in 400[j,L of fresh binding buffer. Cells were then
put into eppendorfs and taken to Wayne State for flow cytometry analysis.

2.11.2 TUNEL Assay
In order to observe DNA fragmentation, an APO-BrdU Tunel (terminal urdinederivatized nick end labeling) assay was preformed using the manufacturer's protocol
(Sigma Chemical Company, Mississauga, Ontario, Canada).

Cells were grown and

treated as previously described. Approximatly ~lxl0 6 cells were washed with PBS and
incubated in 5mL of 1% (w/v) paraformaldehyde in PBS on ice for 15 minutes. The cells
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were washed twice with PBS and re-suspended in 0.5mL of PBS. Cells were added to
5mL of ice-cold 70% (v/v) ethanol and set at -20°C overnight (at least 12 hours).
The next day, ethanol was removed by centrifugation and washed twice using the
wash buffer, provided in the kit. 50uL of DNA labeling solution was prepared for each
sample (lOuL of reaction buffer, 0.75uL of TdT enzyme, 8.0uL of BrdUTP and 31.25uL
of dH20) and cells were incubated for 60minutes in DNA labeling solution at 37°C in a
temperature controlled bath (shaken every 15 minutes). At the end of the incubation
time, 1 .OmL of Rinse Buffer (provided in the kit) was added to each tube followed by
centrifugation. The cells were washed twice with Rinse Buffer and incubated in lOOuL
of antibody staining solution (5uL Alexa Fluor 488 dye labeled anti-BrdU antibody,
95 uL Rinse Buffer) for 30minutes at room temperature. The samples were then resuspended in a total volume of 400uL (rinse buffer) put in eppendorf tubes and taken for
flow cytometry analysis.

2.12 Total and Cytosolic Cell Lysate
Cells were harvested by mechanical dislodging using a rubber policeman and
centrifuged at 500xg for 5 minutes. The supernatant was removed and the pellet was
washed twice with IX PBS pH 7.4 and centrifuged again at 500xg for 5 minutes. The
supernatant was removed and the pellet was re-suspended in 0.4 ml of extraction buffer
(25mM HEPES pH 7.25, 5mM MgCl2, lmM EGTA, 0.1% Triton X 100). The cell
suspension buffer was transferred into a Dounce cell homogenizer. Cells were
homogenized with -20 strokes to produce the total cell lysate. Cytosolic cell lysates
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were obtained by an additional centrifugation at 200xg. The supernatant was collected as
the cytosolic cell lysate.

2.13 Mitochondrial Isolation
Intact mitochondria were isolated from cells using a previously published method
(Li et. al. 2003). Cells were collected by centrifugation at 500xg for 5 minutes. The pellet
was washed twice with ice cold PBS and centrifuged at 250xg. The pellet was resuspended in isolation buffer containing ImM EDTA, lOmM HEPES (pH 7.4) and
250mM sucrose. Cells were homogenized and the disrupted cells were centrifuged for 5
minutes at 600xg at 4°C. The supernatant was collected and centrifuged at 15 OOOxg at
4°C for 5 minutes and the resulting pellet was considered to be crude mitochondria. The
pellet was re-suspended in isolation buffer without EDTA. Mitochondrial suspensions
were kept on ice and all of the experiments were performed within 2 hours of
centrifugation.

2.14 ROS Detection in Isolated Mitochondria
Isolated mitochondria from untreated cells were subjected to direct incubation
with 0.5 uM PST and 5uM Tamoxifen. Also, lOOuM paraquate was added to
mitochondrial preparations as a positive control. Mitochondrial ROS generation was
measured using Amplex Red dye (Sigma Chemical Company, Mississauga, Ontario,
Canada), increase in the fluorescence due to oxidized Amplex Red fluorescence was
approximated to be due to mitochondrial destabilization. This assay utilized horseradish
peroxidase (HRP) to couple Amplex Red oxidation with peroxide reduction. In a 96-well
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micro-titer plate, 0.25mg of mitochondrial suspension was added to a lOOul reaction
mixture containing 0.25M sucrose, ImM MgCl2, lOmM HEPES, lOOmM succinate, 5uM
Amplex Red and 1 unit of HRP per well. Fluorescence of oxidized Amplex Red was
measured at excitation 560nm and emission 590nm using the Spectra Max Gemini XS
which was set to read the wells every 2 min over a total time of 2 hours.

2.15 Whole Cell ROS
Cells were grown on 24-well clear bottom plates until 70% confluence was
established. Cells were treated with varying concentrations of drugs mentioned (PST and
Tamoxifen) and incubated for a period of 48 hrs. Following incubation, lOuM

T-T-

dichlorofluorescin diacetate (H2DCFCA; Molecular Probes, Eugene, OR) was added to
each well and cells were monitored overnight for 18 hrs with readings taken in 10 min
intervals using SoftMax PRO 3.1.2 software on a SpectraMax Gemini XS fluorescent
plate reader at excitation 495nm and emission 530nm. Microsoft Excel software was used
for data representation and statistical analysis.

2.16 Western Blot
2.16.1 Protein Estimation
The concentration of proteins present in cytosolic or mitochondrial cell lysate
samples was estimated using a protocol from BioRad Laboratories. Protein estimation
was conducted by adding lOuL aliquots of each cell lysate sample, 790 oL of water and
200uL of BioRad protein assay reagent into lmL plastic cuvettes. The mixtures were
vortexed and allowed to stand for 10 minutes at room temperature. The absorbance was
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then measured a UV-Visible Spectrophotometer and analyzed at 595 run. A standard
curve was prepared by using various amounts of a standard protein solution (lmg/ml
bovine serum albumin).

2.16.2 SDS-PAGE and Gel Transfer
Protein samples were separated using either 10% or 12% SDS-PAGE (sodium
dodecyl sulphate polyacrylamide gel electrophoresis). A total of 40 ug of protein was
loaded into the gel and run in running buffer (1.44g Glycerine,0.1g SDS, 0.3g Tris-HCl
in 1L of distilled water, pH=8.9 ) for one hour at a constant 30 mAmps and 200V. The
gel was then transferred to a nitrocellulose membrane in transfer buffer (20% methanol,
25mM Tris Base, 0.2M Glycine, pH<8) for one hour at 200mAmps and 80V. The
membrane was then stained with Ponceau S for rapid reversible detection of protein
loaded and an image was scanned.

2.16.3 Immunoblotting Analysis
The membrane was blocked in 5% milk in TBST for one hour at 25°C. The
membrane was then incubated with primary antibody solution (2% milk in TBST, 1:1000
dilution) and incubated for one hour. Then the membrane was washed 3 times with TBST
for 15 min. The membrane was then incubated for one hour with secondary antibody (2%
milk in TBST and a 1:1000 dilution) consisting of anti-mouse conjugated to HRP or antirabbit conjugated HRP. As before, the membrane was subjected to three 15 minute TBST
washes. The chemiluminescent peroxidise substrate reagent and buffer (Sigma Chemical
Company, Mississauga, Ontario, Canada) was prepared and the blot was visualized using the

35

Chemi-Imager v5.5 (Alphatech Inovations) in Dr. Ananvoranich's lab. Spot analyses was
carried out using image J software downloaded directly from the internet.
2.17 Whole Cell Caspase-8 Activation Assay
Whole cell caspase-8 detection assay was purchased from Cell Technology Inc.
Mountain View, CA. As per protocol, treated and un-treated cells were placed in 96 well
black fluorescent plates in 300uL of media. A total of lOuL of the 30 X caspase detection
reagents (FAM-LETD-FMK) was added directly to 300uL of cell suspension. Cells were
incubated for 1 hour at 37°C. After the incubation time the media was decanted by
spinning the plates in a centrifuge and gently flicking the plate. Approximately 300uL of
IX Wash Buffer (provided in kit) was added to each well, centrifuged and removed.
After the final wash lOOuL of Wash Buffer was added at which point the plate was ready
for analysis. The plate was read using a fluoriometer at an excitation of 515nm and
emission of 590nm.

2.18 Long-term Drug Resistance and Viability Study
MCF-7 breast cancer cells were grown and maintained using sub-culturing
techniques, however, 25nM and 50nM PST was added to the media after each culture
splitting for a period of 20 days. After 20 days of 25nM and 50nM PST treatment the
cells were treated with luM PST for 72 hours. At this time luM Hoechst 33342 dye was
added to observe positive nuclear staining as mentioned before.
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2.19 JC-1 Staining
Mitochondrial membrane permeability was visualized using 5,5' ,6,6'-tetrachloro1,1' ,3,3' -tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye purchased from Sigma
Chemical Company, Mississauga, Ontario, Canada and used according to the
manufacturer's protocol and a previously published method (Olichon et. al. 2003). The
cells were grown and treated as previously described. The cells were incubated in media
containing luM of JC-1 dye for 15 minutes and the media was replaced by PBS (floating
cells were re-added after centrifugation). The cells were examined under a fluorescent
microscope and pictures were taken.

2.20 In- vivo Treatment Preparation
Intraperitoneal Placebo treatment consisted of 250uL of sterile peanut oil. PST
treatments were intratumoural and consisted of 5uL of lOmM PST stock solution in a
total volume of 250uL of sterile PBS this was calculated to be approximately 3mg/kg
concentration. Tamoxifen treatments consisted of 20uL of lOmM Tamoxifen stock added
to 250uM steril peanut oil, which was calculated to be approximately 25mg/kg. Peanut
oil was used based on previously published method of Tamoxifen injection (PaineMurrietta et. al. 1997).

2.21 RAG 2M Mouse Care, Xenograft Transplantation and Treatment
For this study, a total of 10 male immunodeficient RAG 2M mice were purchased
from Taconic, Cambridge City, IN. Mice were injected with 60 day slow release 17pestradiol pellets using a trochar device, both purchased from Innovative Research of
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America, Sarasota, FL. The mice were housed in autoclaved cages and fed irradiated
food and autoclaved water. All of the mice were injected sub-cutaneously with 6 x 106
human MCF-7 breast cancer cells and visible tumours formed after 10-14 days. The mice
were then divided into 4 groups: 3 received intraperitoneal Placebo treatment; 2 received
intratumoral PST treatment; 3 received intraperitonial Tamoxifen treatment; and 2
received intratumoural PST + intraperitonial Tamoxifen treatment. The PST treated mice
were given approximately 3mg/kg PST twice weekly and Tamoxifen treated mice were
given 25 mg/kg Tamoxifen 3 times a week for 5 weeks. Periodically, the mice were
weighed and the tumour volume was measured using callipers. One week after the last
treatment, all mice were sacrificed by CO2 asphyxiation according to ethical care
committee protocol.

2.22 Tissue Preparation for Histochemical Analysis
The tissues stored in 10% formalin were moved to 70% ethanol within 24hours
and then processed through a dehydration gradient being put into paraffin-wax blocks.
The tissues were moved through an increasing ethanol gradient and then submerged in
xylene and wax. The following times and concentrations were used: 70% EtOH
overnight; 1 hour 95% EtOH; 1 hour absolute EtOH; 90 minutes xylene; 1 hour
xylene/wax (50:50); wax overnight at 60°C. Wax blocks were assembled by placing a
piece of tumour, liver and kidney from one mouse at the bottom of the mould and then
pouring wax to fill the mould. The mould is then placed in -20°C overnight before it is
ready to be sectioned using a microtome. Microtome sections of 8 microns were cut into
ribbons, which were laid in a 40°C water bath and allowed to stretch out before being
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mounted on a superfrost slide. About 3-4 sections were placed on each slide. The slides
were left overnight on a hot plate at about 55°C.

The slides were then ready for

histochemical analysis.

2.23 Tissue Preparation Revision
When the tissues were prepared and sectioned, it was found that the liver tissues
were over dehydrated. The dehydration of the tissues is irreversible, thus the protocol was
optimized for future work. The revised method is identical to the previous method but the
tissue is subjected to a shorter time in xylene to reduce the amount of dehydration caused
to the tissues. The optimum xylene incubation time was found to be 30 minutes compared
to the 90 minute incubation in the previous method.

2.24 TUNEL Assay With DAPI on Tissue Sections
The Terminal uridine deoxynucleotidyl transferase dUTP Nick End Labelling
(TUNEL) assay was purchased from Sigma Chemical Company Mississauga Ontario .
This assay detects the presence of nicks in the DNA which can be identified by terminal
deoxynucleotidyl transferase, an enzyme that catalyzes the addition of dUTPs that are
secondarily labelled with a marker. These nicks are typically observed in cells that have
undergone apoptosis. DAPI (4',6-diamidino-2-phenylindole) is a fluorescent stain that
intercalates into the minor groove of DNA. Chromatin condensation is consistent with
apoptosis and can be visualized by a concentrated and brighter fluorescence than the
surrounding non-apoptotic nuclei.
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This assay begins with the slide being rehydrated according to the following
procedure: 2x5 min xylene; 2x5min absolute EtOH; 3 min 95% EtOH; 3 min 80% EtOH;
3 min 70% EtOH; 3 min H2O; 3 min PBS. The slides were incubated in primary antibody
solution (40uL Reaction buffer, 3uL TdT enzyme, 24uL BrdUTP, 125uL dH 2 0)
overnight at 4°C. The slides were then washed with Rinse Buffer and incubated in Alexa
Fluor 488 secondary antibody solution (lOuL Alexa Fluor, 190uL Rinse Buffer) for 1
hour at 25°C. The slides were then washed with PBS and mounted using mounting media
containing DAPI nuclear stain.

2.25 Haematoxylin and Eosin
This stain is performed to visualize the morphology of the tissue. The nucleus stains
blue and the cytoplasm stains pink, which gives an overall morphological view of the
tissue. The slides were dewaxed/rehydrated, stained with Harris Haematoxylin (Fischer
Scientific, Kalamazoo MI), dehydrated, and then stained with Eosin Y (EMD Chemicals
Inc., Darmstadt Germany) according to the following procedure: 10 min xylene; 10 min
absolute EtOH; 5 min 95% EtOH; 5 min 70% EtOH; dipped in 50% EtOH; dipped in
30% EtOH; dipped in H2O; 3 min Haematoxylin stain; dipped in H2O; dipped in 30%
EtOH; dipped in 50% EtOH; dipped in 70% EtOH; dipped in 95% EtOH; 3 min Eosin
stain: 10 min absolute EtOH; 10 min xylene. These last two steps are done to completely
dehydrate the tissues. The slides were then mounted with coverslips using Cytoseal 60
and viewed on a light microscope.
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2.26 Tissue Preparation for Biochemical Analysis
The flash-frozen tissue samples were unfrozen at 4°C and homogenized in 3
volumes of homogenization buffer (50mM Tris-HCl, 150mM Nail, ImM EDTA, ImM
PMSF, ImM benzamidine, lOug/ml pepstatin A and lOug/ml leupeptin, 2% beta
mercaptoethanol) using a Sorvall Omni-Mixer at 4°C.15 The samples were centrifuged at
2700 x g for 1 Omin at 4°C to separate the nuclear and cell debris from the supernatant.
The supernatant was then centrifuged at 10,000xg for 10 minutes at 4°C to obtain the
mitochondrial

pellet and the post-mitochondrial

cytoplasmic

supernatant.

The

mitochondrial pellet was resuspended in the homogenisation buffer; both fractions were
used for biochemical analysis using western blot procedure.
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CHAPTER 3: RESULTS

3.1: In-vitro Apoptotic Synergy Exhibited by PST and Tamoxifen
Pancratistatin has been shown to have the ability of activating apoptosis in cancer
cells specifically through the destabilization of cancer cell mitochondria. Tamoxifen
which is primarily an anti-estrogen treatment for breast cancer, has recently been
discovered to induce apoptosis through biochemical pathways unrelated to the estrogen
receptor (Mandlekar, Kong 2001). The electron transport chain of cancer cell
mitochondria has been found to be disrupted by Tamoxifen through binding of
Tamoxifen to the flavomononucleotide binding site in complex 1 (Moreira et. al. 2006).
Due to these observations PST and Tamoxifen were considered as a potential
combination therapy in both estrogen receptor +/- breast cancers.

3.1.1 Susceptibility of MCF-7 Cells to Apoptosis by PST Treatment

Several cancer cell lines are susceptible to PST-induced apoptosis at luM
concentration including: Jurkat (B-cell lymphoma), SHSY-5Y (neuroblastoma), 5123 (rat
hepatoma) as reported by our laboratory (Pandey et. al. 2001, McLachlan et. al. 2005).
Furthermore, we have shown that PST specifically induces apoptosis in cancer cells with
minimal effect on normal cell lines (McLachlan et. al. 2005).
To evaluate the effect of PST on estrogen dependent breast cancer cells, we
treated MCF-7 (adenocarcinoma) with concentrations of luM and 500nM PST for a
period of 72 hours. Following treatment we stained the cells with cell permeable Hoechst
33342 dye to semi-quantitatively determine the number of cells exhibiting the hallmark
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feature of apoptosis: nuclear condensation. Figure 3-1 shows that 0.5uM PST
concentration caused approximately 45% apoptosis at 72 hours and 1 uM PST at this time
point caused 60% apoptosis in MCF-7 cells.

3.1.2 Synergistic Action of PST and Tamoxifen in ER+ MCF-7 Cells
Research from as early as the 1970's shows that 50-70% of invasive breast cancer
expresses estrogen receptor, based on pooled analysis of 400 patients (McGuire et. al.
1975). Of these estrogen receptor positive breast cancer patients 50-60% responded well
to endocrine therapy (McGuire et. al. 1975). Tamoxifen as a therapy has selectivity for
the estrogen receptor and therefore shows little toxicity to normal cells (Duffy 2005).
This initially sparked our interest in examining combinatorial therapy of Tamoxifen and
PST on estrogen receptor positive breast cancer (MCF-7). We aimed to determine the
effect of adding PST and Tamoxifen in combination to the estrogen receptor positive
MCF-7 cell line to evaluate the apoptotic response to combination therapy relative to
each compound separately.
Breast adenocarcinoma positive for ER was treated with Tamoxifen at luM,
5uM, and 10|_iM concentrations for 72 hours and stained with Hoechst 33342 dye to
generate relative apoptotic indices. As shown in figure 3-1 and 3-2a 5uM Tamoxifen
treatment did not cause apoptosis as compared to control; only the higher concentration
of lOuM Tamoxifen causes significant apoptosis in this cell line. We then treated MCF-7
cells with low dose of 0.5uM PST in combination with luM, 5uM and 10|j,M Tamoxifen
and the effective dose of luM PST in combination with 1, 5, lOuM Tamoxifen for a
period of 72 hours. Figure 3-2b shows the result of combinatorial treatment of 5uM
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Tamoxifen and luM PST after 72 hours: a significant increase in apoptosis is evident
when compared to Tamoxifen and PST on their own (figure 3-1). The apoptotic index of
combined treatment of luM PST and 5uM Tamoxifen increased by approximately 20%
when compared to luM PST alone (figure 3-1, 3-2b). Similar results were observed
when MCF-7 cells were treated with 0.5uM PST in combination with 5uM Tamoxifen. A
concentration of 0.5 uM PST on its own induced approximately 45% apoptosis after of 72
hours treatment; however, in combination with 5uM Tamoxifen (the concentration were
no effect was observed), the apoptotic index increased to 65% apoptosis, which
corresponds to an apoptotic increase of 20% (figure 3-1,3-2a, 3-2c).
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Figure 3-1: Apoptotic Index: Dose Response of MCF-7 cells to Pancratistatin and
Tamoxifen
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Figure 3-1: Apoptotic Index: Dose response of MCF-7 cells to Pancratistatin and Tamoxifen. MCF7 cells were treated with PST and Tamoxifen for 72 hours and stained with Hoechst 333423 dye. The
number of apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated from
a minimum of 500 cells. Standard error was calculated using data from a minimum of three separate
experiments.

Figure 3-2a: Synergistic response of MCF-7 cells to Pancratistatin and Tamoxifen
Treatment MCF-7
Control

0:5pM PST
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Figure 3-2a: Synergistic response of MCF-7 cells to Pancratistatin and Tamoxifen treatment MCF-7.
MCF-7 cells were treated with PST and tamoxifen for 72 hours and stained with Hoechst 33342 dye to
examine nuclear morphology.
Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.
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Figure 3-2b: Apoptotic Index: Synergy of PST and Tamoxifen at High Dose PST
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Figure 3-2b: Apoptotic Index: Synergy of PST and Tamoxifen at high dose PST. MCF-7 cells were
treated in combination with 1 uM PST and various concentrations of Tamoxifen for 72 hours and stained
with Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of
apoptotic cells was calculated from a minimum of 500 cells. Standard error was calculated using data from
a minimum of three separate sets of experiments.

Figure 3-2c: Apoptotic Index: Synergy of PST and Tamoxifen at Low Dose PST
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Figure 3-2c: Apoptotic Index: Synergy of PST and Tamoxifen at low dose PST. MCF-7 cells were
treated in combination with 0.5 uM PST and various concentrations of Tamoxifen for 72 hours and stained
with Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of
apoptotic cells was calculated from a minimum of 500 cells. Standard error was calculated using data from
a minimum of three separate sets of experiments.
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3.1.3 Induction of Apoptosis in ER- Hs578-T Cells by PST Treatment
Estrogen receptor negative Hs578-T cells were treated with 0.5uM and luM PST
treatment for 72 hours and quantified by Hoechst-33342 dye in order to examine nuclear
condensation and develop apoptotic indexes to establish the relative apoptotic effect as
compared to a control. Apoptotic nuclear morphology was observed upon the addition of
0.5uM and luM PST in the form of condensed bright nuclei (figure 3-3a). As observed
in figure 3-3b, 0.5 uM PST treatment caused 20% apoptosis while 1 uM PST treatment
exhibited approximately 45% apoptosis for 72 hours.

3.1.4 Synergistic Action of PST and Tamoxifen in ER- Hs578-T Cells
Tamoxifen, an estrogen receptor antagonist, has been recently observed to induce
apoptosis

by

directly

destabilizing

cancer

cell

mitochondria

through

the

flavomononucleotide (FMN) binding site on complex 1 of the electron transport chain
(Moreira et. al. 2006). Here, the effect of Tamoxifen was considered in estrogen receptor
negative cells in combination with PST in order to observe a potential to exploit the
Tamoxifen targeted mitochondrial membrane dysfunction. To examine whether a
synergistic relationship exists between these agents, various concentrations of PST and
Tamoxifen were combined and incubated with Hs578-T cells for 72 hours and
quantitatively analyzed by Hoechst 33342 staining as per protocol. Figure 3-3a shows
that the addition of lOuM Tamoxifen over 72 hours exhibited little apoptotic nuclear
morphology when compared to control; however, the addition of 0.5uM PST in
combination with lOuM Tamoxifen increased the apoptotic response of the 0.5uM PST
treatment.
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Furthermore, apoptotic indices were established from counting the number of
cells which demonstrate condensed apoptotic nuclei. As observed in figure 3-3b Hs578-T
cells treated with 10uM Tamoxifen for 72 hours exhibited minimal apoptotic
morphology. The combined treatment of 0.5 uM PST and lOuM Tamoxifen for 72 hours
exhibited approximately 40% apoptosis which corresponds to a 20% increase from
0.5uM PST on its own (figure 3-3b).
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Figure 3-3a: Synergistic Response of Hs578-T Cells to PST and Tamoxifen
Treatment for 72 Hours
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Figure 3-3a: Synergistic response of Hs578-T cells to Pancratistatin and Tamoxifen treatment.
Hs578-T cells were treated with various concentrations of PST and Tamoxifen for 72 hours and stained
with Hoechst 33342 dye to examine nuclear morphology. Fluorescent pictures were taken at 40x
magnification. Nuclear condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 3-3b: Apoptotic Index: Synergistic response of Hs578-T cells to PST and
Tamoxifen Treatment
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Figure 3-3b: Apoptotic Index: Synergistic response of Hs578-T cells to Pancratistatin and
Tamoxifen treatment. Hs578-T cells were treated in combination with various PST and Tamoxifen
concentrations for 72 hours and stained with Hoechst 33342 dye. The number of apoptotic nuclei was
counted and the average percentage of apoptotic cells was calculated from a minimum of 500 cells.
Standard error was calculated using data from a minimum of three separate sets of experiments.
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3.1.5 NHF Cells Un-effected by Combined PST and Tamoxifen Treatment

Minimal toxicity to normal cells is an important characteristic in noval
chemotherapeutic strategies to avoid the harsh side effects that arise from current cancer
therapies. Toxicity to normal cells due to current chemotherapies such as taxol and
topoisomerase II inhibitors has been attributed with re-occurrence of disease and
establishment of secondary tumors (Cunha et. al. 2001, Boos, Stopper 2000). Therefore
compounds which reduce the risk of side-effects are the focus of modern research. As
previously mentioned PST has been shown to exhibit no toxic effect to normal tissue
(Pandey et. al. 2001, McLachlan et. al. 2005). Furthermore, Tamoxifen has been reported
to exhibit minimal toxicity to normal tissue (Duffy 2005). Therefore the combinatorial
treatment of both compounds was considered in a normal non-cancerous cell line to
examine the potential for toxicity.
To determine the effect of combined PST and Tamoxifen treatment on normal cell
lines we chose to treat normal human fibroblasts (NHF). There was no evidence
suggesting toxicity of combination treatment to these cells after 72 hours. Figure 3-4a
and 3-4b shows that combinatorial treatments of lOuM Tamoxifen and luM PST did not
induce significant nuclear condensation when compared to untreated NHF cells.
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Figure 3-4a: Combinatorial Treatment of PST and Tamoxifen in NHF Cells
Control
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1|JMPST

1pMPST+10jjMTam

Figure 3-4a: Combinatorial Treatment of PST and Tamoxifen in NHF. Cells NHF cells were treated
with various concentrations of PST and tamoxifen for 72 hours and stained with Hoechst 33342 dye to
examine nuclear morphology.
Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 3-4b: Apoptotic Index: Combinatorial Treatment of NHF Cells to PST and
Tamoxifen for 72 Hour
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Figure 3-4b: Apoptotic Index: Combinatorial Treatment of NHF Cells to PST and Tamoxifen for 72
Hour, treated for 72 hours and stained with Hoechst 33342 dye. The number of apoptotic nuclei was
counted and the average percentage of apoptotic cells was calculated from a minimum of 500 cells.
Standard error was calculated using data from a minimum of three separate sets of experiments.
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3.1.6 Quantitative Analysis of Apoptotic Synergy in MCF-7 Cells
The synergistic effect in MCF-7 cells was quantitatively analyzed by flow
cytometry utilizing Annexin-V FITC conjugate binding. MCF-7 cells were treated with
0.5uM PST and/or 5uM Tamoxifen for a period of 72 hours and incubated with AnnexinV FITC conjugate. Percent positive staining was obtained from a population of 20 000
cells. Figure 3-5a shows that treatment with 5uM Tamoxifen resulted in 14.27% positive
Annexin-V staining, which is not a significant increase over control cells which stained
13.88% Annexin-V positive. Furthermore figure 3-5a shows that treatment with 0.5uM
PST resulted in 34.45% positive Annexin-V staining in MCF-7 cells and the combined
treatment of 0.5uM PST and 5uM Tamoxifen resulted in 52.63% Annexin-V positive
staining which corresponds to a 20% increase from the single treatment with PST.
The level of DNA fragmentation was investigated by TUNEL assay and
quantified by flow cytometry. MCF-7 cells were treated with 0.5 uM PST and/or 5uM
Tamoxifen for 72 hours upon which the TUNEL assay was performed as per
manufacturer's protocol. Cells were properly gated and 20 000 cells were analyzed.
Figure 3-5b shows that 11.85% of untreated MCF-7 cells were positively stained for
DNA fragmentation and 5uM Tamoxifen treatment resulted in 15.78% positive staining.
Furthermore, figure 3-5b demonstrates that MCF-7 cells treated with 0.5 uM PST resulted
in 44.29% positive staining, while the combination of 0.5uM PST and 5uM Tamoxifen
resulted in 48.88% of cells to stain positively.
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Figure 3-5a: Flow Cytometry: Annexin-V Analysis of PST and Tamoxifen Synergy
in MCF-7 Cells
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Figure 3-5a: Flow Cytometry: Annexin-V analysis of PST and Tamoxifen synergy in MCF-7 cells.
MCF-7 cells were treated with 0.5uM PST, 5nM Tamoxifen and a combination of both for 72 hours. Total
cell counts of 20,000 were gated and analyzed by flow cytometry operator. Annexin V-FITC positive cells
were then taken as % Gated.

Figure 3-5b: Flow Cytometry: TUNEL Analysis of PST and Tamoxifen Synergy in
MCF-7 Cells
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Figure 3-5b: Flow Cytometry: TUNEL analysis of PST and Tamoxifen synergy in MCF-7 cells. MCF7 cells were treated with 0.5 uM PST, 5uM Tamoxifen and a combination of both for 72 hours. Total cell
counts of 20,000 were gated and analyzed by flow cytometry operator. TUNEL positive cells were then
taken as % Gated.
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3.1.7 Whole Cell ROS Increases upon Combinatorial PST and Tamoxifen
Treatment
Increase in whole cell ROS is attributed to the dysfunction of the mitochondrial
membrane and eminent apoptosis (Somayajulu et. al. 2005). Whole cell ROS was
measured by the fluorometric assay using H2DCFDA fluorophore. Cancerous and noncancerous cell lines were treated with PST and Tamoxifen upon which relative whole cell
ROS was measured.
MCF-7 (ER+) and Hs578-T (ER-) were grown on 24-well culture plates and
treated with 0.5uM PST, 5uM Tamoxifen or a combination of both for a period of 24
hours, upon which whole cell ROS was measured as per protocol. As observed in figure
3-6a, the combined treatment of 0.5uM PST and 5uM Tamoxifen increased the relative
amount of ROS production in MCF-7 cells more so then either drug on its own. Similar
results were obtained in the ER- Hs578-T cell line (figure 3-6b) as combined treatment of
0.5uM PST and 5uM increased the relative amount of ROS in greater amount then either
drug alone. Furthermore to test the effect of combined PST and Tamoxifen in normal
human fibroblast (NHF) cells we treated them with higher doses of PST and Tamoxifen
to determine if there are any changes in the total ROS production. As was observed in
figure 3-6c, there was no significant increase from control upon the addition of luM
PST, lOuM Tamoxifen and a combination of both, at these concentrations.
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Figure 3-6a: Whole Cell ROS of MCF-7 Cells Treated With PST and Tamoxifen
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Figure 3-6a: Whole Cell ROS of MCF-7 cells treated with PST and Tamoxifen. MCF-7 cells were
incubated with 0.5 [iM PST, 5uM Tamoxifen and a combination of both for a period of 24 hours then
incubated with H2DCFDA dye and monitored by a fluorometer for a period of 18 hours. Readings were
taken in intervals of 10 minutes. Error bars were generated by the standard deviation between 3 separate
trials of the experiment.

Figure 3-6b: Whole Cell ROS of Hs578-T Cells Treated With PST and Tamoxifen
1600

• Control
• 5|iM TAM
r
0.5nM PST
x 0.5|iM PST+ 5llMT

1400
1200
1000 -—

i

X
800

TT

E
cr

600
T

x

400

T M

J

" i i iN
*4

* T ± I
I

T

T

*

Z *

200

{ H j i h n i J
0

*•

0

200

400

600

800

1000

1200

Time (min)

Figure 3-6b: Whole Cell ROS of Hs578-T cells treated with PST and Tamoxifen. Hs578-T cells were
incubated with 0.5 uM PST, 5[xM Tamoxifen and a combination of both for a period of 24 hours then
incubated with H2DCFDA dye and monitored by a fluorometer for a period of 18 hours. Readings were
taken in intervals of 10 minutes. Error bars were generated by the standard deviation between 3 trials of the
experiment.
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Figure 3-6c: Whole Cell ROS of NHF cells treated with PST and Tamoxifen
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Figure 3-6c: Whole Cell ROS of NHF cells treated with PST and Tamoxifen. NHF cells were
incubated with l^iM PST, lO^M Tamoxifen and a combination of both for a period of 24 hours then
incubated with H2DCFDA dye and monitored by a fluorometer for a period of 18 hours. Readings were
taken in intervals of 10 minutes. Error bars were generated by the standard deviation between 3 trials of the
experiment.

56

3.1.8 Mitochondrial membrane potential collapse upon treatment of PST and
Tamoxifen
As previously mentioned, increase in ROS generation is indicative of
mitochondrial dysfunction within the cell. In order to determine if mitochondria are
destabilized following treatment we used a mitochondria permeable assay. This assay
uses a cationic JC-1 dye, which localizes to mitochondria with adequate mitochondrial
membrane potential and is retained within this membrane were it gives off a red
fluorescent stain, when not localized to mitochondria JC-1 dye will fluoresce green in the
cytosol. Both ER+ and ER- breast cancer cell lines were treated at the previously
determined doses of PST (0.5uM) and Tamoxifen (5uM) which exhibit greatest
synergistic behavior, for 48 hours. Normal human fibroblasts were treated as a control to
compare the effect of the treatment.
In figure 3-7a clear red punctuate staining is observed in both the control and 48h
Tamoxifen treated MCF-7 cells. It is evident from figure 3-7a that the red mitochondrial
staining becomes relatively more diffuse in 0.5 uM PST treated cells. Red punctuate
mitochondrial staining is even more diffuse in the combinatorial treatment of 0.5uM PST
and 5uM Tamoxifen as is evident by the increase in green background staining (figure 37a).
As can be seen from figure 3-7b, in Hs578-T cells, control and lOuM Tamoxifen
exhibited approximately the same red punctuate staining; however, the JC-1 stain of the
combined treatment of 0.5uM PST and lOuM Tamoxifen indicate greater diffuse red
staining then either of the compounds separately. Furthermore normal human fibroblast
cells did not exhibit substantial changes in the amount of red punctuate JC-1 staining as
shown in figure 3-7c, when treated with 0.5uM PST and 5uM Tamoxifen.
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Figure 3-7a: Mitochondrial Membrane Permeability in MCF-7 Cells Treated by
PST and Tamoxifen: JC-1 Staining
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Figure 3-7a: Mitochondrial membrane permeability in MCF-7 cells treated by PST and Tamoxifen:
JC-1 staining. MCF-7 cells were treated with 0.5 jiM PST and 5(iM Tamoxifen for a period of 48 hours at
which point JC-1 dye was applied to the cells to examine mitochondrial membrane potential. Fluorescent
pictures were taken at 400x magnification. Bright red florescence is indicative of healthy mitochondria
with intact membrane potential.
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Figure 3-7b: Mitochondrial Membrane Permeability in Hs578-T Cells Treated by
PST and Tamoxifen: JC-1 Staining
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Figure 3-7b: Mitochondrial membrane permeability in Hs578-T cells treated by PST and
Tamoxifen: JC-1 staining. Hs578-T cells were treated with 0.5u.M PST and lOfiM Tamoxifen for a
period of 48 hours at which point JC-1 dye was applied to the cells to examine mitochondrial membrane
potential. Fluorescent pictures were taken at 400x magnification. Bright red florescence is indicative of
healthy mitochondria with intact membrane potential.
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Figure 3-7c: Mitochondrial Membrane Permeability in NHF Cells Treated by PST
and Tamoxifen: JC-1 Staining
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Figure 3-7c: Mitochondrial membrane permeability in NHF cells treated by PST and Tamoxifen:
JC-1 staining. NHF cells were treated with 0.5^M PST and 5fiM Tamoxifen for a period of 48 hours at
which point JC-1 dye was applied to the cells to examine mitochondrial membrane potential. Fluorescent
pictures were taken at 400x magnification. Bright red florescence is indicative of healthy mitochondria
with intact membrane potential.
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3.1.9 Mitochondria as the Target for PST and Tamoxifen Induced Apoptosis
PST has previously been shown to exhibit its activity directly on the mitochondria
of cancerous cells and Tamoxifen has been observed to have mitochondrial targets
independent of estrogen receptor activity. Therefore, to test the effect of both compounds
on the mitochondria directly, we isolated mitochondria from MCF-7, Hs578-T and NHF
cell lines and treated their isolated mitochondria directly with PST, Tamoxifen and a
combination of both for a total of 1.5 hours. Paraquat which increases mitochondrial
ROS was used as a positive control. Upon treatment of mitochondria with the compounds
a fluorometric assay was utilized. This assay works by coupling a reaction involving:
reduction of Amplex Red dye reagent with oxidation of hydrogen peroxide through the
action of horse radish peroxidase enzyme.
Figure 3-8a shows that the treatment of MCF-7 mitochondria with 5uM
Tamoxifen did not generate significant mitochondrial ROS increases when compared to
control and MCF-7 mitochondria treated with 0.5 uM PST increases the relative amount
of mitochondrial ROS. Figure 3-8a demonstrates that 5uM Tamoxifen and 0.5uM PST
significantly increase the relative amount of mitochondrial ROS, more so then either
compound separately.
To test the mitochondrial response in estrogen receptor negative cells, we isolated
mitochondria from Hs578-T cells and incubated them with the various treatments. As can
be seen in figure 3-8b the mitochondrial ROS response in Hs578-T cells is similar to that
observed in the estrogen receptor positive MCF-7 mitochondria, where the addition of the
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double treatment 5uM Tamoxifen and 0.5u PST increased the relative ROS in greater
amount then either compound separately.
To investigate the response of normal "healthy" mitochondria, we isolated
mitochondrial fractions from normal human fibroblast cells and treated them in the same
manner as the ER- and ER+ cell lines. As clearly shown in figure 3-8c, there was no
significant ROS increase from control when isolated mitochondria from NHF cells were
treated with 0.5uM PST, 5uM Tamoxifen and both. To observe increased mitochondrial
ROS response from the mitochondrial preparations, we treated them with lOOuM
Paraquat, which was observed to increase the ROS significantly (figure 3-8c).
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Figure 3-8a: Mitochondrial ROS Measurement Isolated From MCF-7 Cells
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Figure 3-8a: Mitochondrial ROS measurement isolated from MCF-7 cells. Isolated MCF-7 cell
mitochondria were incubated directly with 0.5 uM PST, 5\iM Tamoxifen and a combination of both. The
amplex red/HRP mitochondrial ROS detection assay was performed over a period 1.5 hours. Readings
were taken every 2 minutes using a fluorometer. Standard deviations were calculated upon the completion
of 3 separate experiments.
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Figure 3-8b: Mitochondrial ROS measurement isolated from Hs578-T cells
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Figure 3-8b: Mitochondrial ROS measurement isolated from Hs578-T cells. Isolated Hs578-T cell
mitochondria were incubated directly with 0.5 ^M PST, 5[xM Tamoxifen and a combination of both. The
amplex red/HRP mitochondrial ROS detection assay was performed over a period 1.5 hours. Readings
were taken every 2 minutes using a fluorometer. Standard deviations were calculated upon the completion
of 3 separate experiments.
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Figure 3-8c: Mitochondrial ROS Measurement Isolated From NHF Cells
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Figure 3-8c: Mitochondrial ROS measurement isolated from NHF cells. Isolated NHF cell
mitochondria were incubated directly with 0.5 uM PST, 5uM Tamoxifen and a combination of both. The
amplex red/HRP mitochondrial ROS detection assay was performed over a period 1.5 hours. Readings
were taken every 2 minutes using a fluorometer. Standard deviations were calculated upon the completion
of 3 separate experiments.
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3.1.10 PST and Tamoxifen Cause Release of Cytochrome c Synergistically in
Isolated MCF-7 Mitochondria
To investigate Cytochrome c release from isolated mitochondria after PST
treatment, we prepared isolated mitochondrial fractions from MCF-7 cells. Polyclonal
anti-Cytochrome c antibody was used to probe for Cytochrome c retained within the
mitochondria after the 2 hour incubation period. Anti-Succinate dehydrogenase antibody
was used as a mitochondrial loading control. The concentrations used to treat isolated
mitochondrial fractions include: 0.5uM, luM, 2uM, 4uM and 8uM PST and figure
shows 3-9a that 0.5uM PST did not significantly reduce the amount of Cytochrome c
retained within the mitochondria. Figure 3-9a shows that concentrations of 1 uM PST and
greater were required to significantly reduce the amount of Cytochrome c retained in the
mitochondrial pellets.
To study the relative effect of combined PST and Tamoxifen treatment on isolated
mitochondria preparations, we incubated mitochondrial pellets prepared from MCF-cells,
for a period of 2 hours, with 0.5uM PST and 5uM Tamoxifen. It was observed from
figure 3-9b that 0.5uM PST did not reduce the amount of Cytochrome c retained within
the mitochondria when compared with the control. As shown in figure 3-9b 5uM
Tamoxifen did not significantly reduce the amount of Cytochrome c retained in the
mitochondrial pellets, however the combined treatment of 0.5 uM PST and 5uM
Tamoxifen was sufficient to decrease the amount of Cytochrome c retained within the
mitochondria.
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Figure 3-9a: Retention of Cytochrome c Upon Treatment of PST Directly on
Isolated MCF-7 Mitochondria.
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Figure 3-9a: Retention of Cytochrome c upon treatment of PST directly on MCF-7 isolated
mitochondria. Approximately 100|xg of mitochondrial protein was incubated with indicated concentrations
of PST for a period of 2 hours upon which time mitochondrial pellets were loaded onto a polyacrylamid gel
and blotted for cytochrome C and succinate dehydrogenase.

Figure 3-9b: Retention of Cytochrome c Upon the Combinatorial Treatment of PST
and Tamoxifen Directly on Isolated MCF-7 Mitochondria.
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0.5tiM PST + 5[JM Tarn

Anti-Cyt C ->

Anti-SDH ->

Figure 3-9b: Retention of Cytochrome C upon the combinatorial treatment of PST and Tamoxifen
directly on MCF-7 isolated mitochondria. Approximately 100[xg of mitochondrial protein was incubated
with 0.5^M PST and 5\iM Tamoxfen for a period of 2 hours upon which time mitochondrial pellets were
loaded onto a polyacrylamid gel and blotted for cytochrome C and succinate dehydrogenase.
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3.2 Insights into the Mechanism of PST Induced Apoptosis
Apoptosis induction caused by PST has been well established in our lab, however
specific questions with respect to the internal biochemical response remain. We looked at
levels of pro/anti-apoptotic proteins and caspase-8 activation in MCF-7, Hs578-T and
NHF cells. Furthermore we examined MCF-7 cells for resistance over prolonged sublethal PST incubation.

3.2.1 Pro/Anti-apoptotic Protein Expression and Localization Upon PST Treatment
in Hs578-T, MCF-7 and NHF Cells
To gain insights into biochemical mechanism of PST we probed cytosolic and
mitochondrial fractions of MCF-7, Hs578-T and NHF cells with specific bcl-2 pro and
anti-apoptotic protein antibodies to check for cellular expression and localization. Cells
were treated with 1 uM PST for 48 hours, homogenized and fractionated as per protocol,
40ug of proteins from the separate fractions were analyzed by western blot for the
indicated antibody as per protocol. The polyclonal antibodies used for the western blot
analysis include: anti-Bax, anti-Bad, anti-Bcl-2, anti-Bcl-xl, anti-Cytochrome C and antiSuccinate dehydrogenase.
We investigated the response of MCF-7 cells to 1 uM PST treatment with respect
to localization and expression of pro/anti-apoptotic proteins in cytosolic and
mitochondrial fractions. Figure 3-10a shows that the cytosolic fraction of MCF-7 cells
treated with 1 uM PST for 48 hours exhibited significantly higher amounts of Bad proapoptotic protein and significantly lower amounts of Bax pro-apoptotic protein as
compared to the control un-treated cells. The mitochondrial fraction was probed for
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Cytochrome c and Bax and it was observed in figure 3-10b that the levels of cytochrome
c decreased and the levels of Bax increased in the treated cells.
The breast cancer cell line Hs578-T was also analyzed for the expression anti/proapoptotic proteins under the same conditions as the MCF-7 cells to co-relate the overall
response to treatment with luM PST for 48 hours. As observed in figure 3-10b the
cytosolic fraction levels of Bcl-2 are decreased and the levels of both Bax and Bad
increased. In addition figure 3-10b shows that in mitochondrial fractions the levels of
Cytochrome c is decreased and levels of Bax are increase in the treated Hs578-T cells.
Analysis of pro/anti-apoptotic proteins in normal human fibroblast cells (NHF)
revealed no significant changes in protein expression and localization as can be seen in
figure 3-lla and 3-llb.
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Figure 3-10a: Cytosolic Fraction of MCF-7 Cells Treated with luM PST
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Figure 3-10a: Cytosolic fraction of MCF-7 cells treated with luM PST. MCF-7 cells were treated for a
period of 48 hours. Cells were harvested and cytosolic fractions were isolated as per protocol. Western
blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the
relative treated to control ratio (right column).

Figure 3-10b: Mitochondrial Fraction of MCF-7 Cells Treated with luM PST
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Figure 3-10b: Mitochondrial fraction of MCF-7 cells treated with luM PST. MCF-7 cells were treated
for a period of 48 hours. Cells were harvested and mitochondrial fractions were isolated as per protocol.
Western blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to
analyze the relative treated to control ratio (right column).
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Figure 3-lla: Cytosolic fraction of Hs578-T Treated with luM PST
Control Treated
Anti-Bcl-2 ->
Anti-Bax ->
Anti-Bad->
i

Anti-Actin ->
Anti-Cyt C ->

Cytosol Hs578-T
i Treat/Con
Bcl2
0.306359
Bax
0.555211
Bad
7.215755
Actin
1.267236
Cyt c
4.082372

Figure 3-lla: Cytosolic fraction of Hs578-T cells treated with luM PST. Hs578-T cells were treated for
a period of 48 hours. Cells were harvested and cytosolic fractions were isolated as per protocol. Western
blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the
relative treated to control ratio (right column).

Figure 3-llb: Mitochondrial Fraction of Hs578-T Cells Treated with l u M PST
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Figure 3-llb: Mitochondrial fraction of Hs578-T cells treated with luM PST. Hs578-T cells were
treated for a period of 48 hours. Cells were harvested and mitochondrial fractions were isolated as per
protocol. Western blots were then run as per protocol and blotted for specified antibodies. ImageJ was used
to analyze the relative treated to control ratio (right column).
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Figure 3-12a: Cytosolic Fraction of NHF Treated with luM PST
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Figure 3-12a: Cytosolic fraction of NHF cells treated with luM PST. NHF cells were treated for a
period of 48 hours. Cells were harvested and cytosolc fractions were isolated as per protocol. Western blots
were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the relative
treated to control ratio (right column).

Figure 3-12b: Mitochondrial Fraction of NHF Cells Treated with l u M PST
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Figure 3-12b: Mitochondrial fraction of NHF cells treated with luM PST. NHF cells were treated for a
period of 48 hours. Cells were harvested and mitochondrial fractions were isolated as per protocol. Western
blots were then run as per protocol and blotted for specified antibodies. ImageJ was used to analyze the
relative treated to control ratio (right column).
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3.2.2 Hs-578-T and MCF-7 Cells Exhibit Late Caspase-8 Activation
The analysis of live cell caspase-8 activation was investigated in MCF-7, Hs578T and NHF cells. The incubation of 1 uM PST for the indicated time points revealed late
caspase-8 activation in both cancer cell lines (MCF-7 and Hs578-T). Figure 3-13a shows
that MCF-7 cells exhibit late (24 hour) caspase-8 activation. As can be observed in figure
3-13b the Hs578-T cells exhibit significant caspase-8 activation at 48 hours.
Furthermore, as shown in figure 3-13c, no caspase-8 activation was observed in luM
PST treated NHF cells.
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Figure 3-13a: MCF-7 Caspase-8 Live Assay
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Figure 3-13a: MCF-7 caspase-8 live assay. MCF-7 cells were incubated with luM PST for the indicated
times at which point a cell permeable FAM-LETD-FMK substrate was added to detect the relative
fluorescence using a flouriometer set at excitation 488nm and emission 520nm. After the assay cells were
counted and the relative fluorescent units per 10,000 cells was expressed.

Figure 3-13b: Hs578-T Caspase-8 Live Assay
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Figure 3-13b: Hs578-T caspase-8 live assay. Hs578-T cells were incubated with luM PST for the
indicated times at which point a cell permeable FAM-LETD-FMK substrate was added to detect the
relative fluorescence using a flouriometer set at excitation 488nm and emission 520nm. After the assay
cells were counted and the relative fluorescent units per 10,000 cells was expressed.
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Figure 3-13c: NHF Caspase-8 Live Assay
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Figure 3-13c: NHF caspase-8 live assay. NHF cells were incubated with 1 uM PST for the indicated times
at which point a cell permeable FAM-LETD-FMK substrate was added to detect the relative fluorescence
using a flouriometer set at excitation 488nm and emission 520nm. After the assay cells were counted and
the relative fluorescent units per 10,000 cells was expressed.
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3.2.3 MCF-7 Cells Do Not Exhibit Resistance to PST
While the overall response rate to treatment can be high in breast cancer cells, the
duration of response is relatively short, and it has been observed that initially responsive
breast tumors acquire a multidrug resistance phenotype (Trock et. al. 1997). This
phenotype is frequently characterized by a cross-resistance to drugs to which the tumors
have not been exposed. The development of a multidrug resistant phenotype in metastatic
breast cancer is primarily responsible for the failure of current treatment regimens (Trock
et. al. 1997).
To test the potential of resistance to PST by MCF-7 cells we pre-incubated these
cells with sub-lethal doses of PST and after a period of time we challenged these cells
with the lethal luM dose. MCF-7 cells were treated with 25nM and 50nM PST for 20
days upon which the cells were challenged with luM PST for 72 hours. After the 72 hour
incubation period MCF-7 cells were treated with the lethal dose of luM PST. Cells were
then incubated with Hoechst 33342 dye and stained nuclei counted. Figure 3-14 shows
that there was no difference in the degree of apoptosis induction between MCF-7 cells
pre-treated with sub-lethal doses of PST and MCF-7 control (not pre-treated), as both
types of cells exhibited the same apoptotic response upon 72 hour incubation with 1 uM
PST.
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Figure 3-14: Apoptotic Index of Resistance to PST Treatment
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Figure 3-14: Apoptotic Index of Resistance to PST Treatment. MCF-7 cells were pre-treated for 20
days with sub-lethal 25 and 50nM PST treatments. After 20 days cells were re-plated and treated with
lethal dose ofluM PST for 72 hours. Hoechst 33342 dye was added and the number of cells exhibiting
apoptotic nuclear morphology was counted.
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3.3 Preliminary Study of in-vivo PST and Tamoxifen Induced Apoptosis
To test the effect of PST and Tamoxifen in-vivo, a RAG 2M mouse model was
developed. Ten immunocompromised RAG 2M mice with disrupted recombination
activating gene-2 were used in the model. Time release 17p-estradiol pellets were
injected sub-cutaneously into the neck of each mouse using a trochar device to achieve
maximum tumor growth (Webb et. al. 2007). Tumors were generated by injecting 6 x
10A6 MCF-7 cells subcutaneously into hind flank each mouse. Tumors were allowed to
grow for approximately 2 weeks after initial injection until an approximate size of 5mm
in diameter was visible. Mice were then selected and grouped according to relative tumor
size for treatments. Four groups were generated with placebo (peanut oil), PST (3mg/kg),
Tamoxifen (25mg/kg), and both PST (3mg/kg) and Tamoxifen (25mg/kg). Intra tumoral
PST injections were given twice a week and intra peritoneal Tamoxifen injections were
given 3 times up to a total of 10 PST injections and 14 Tamoxifen injections over 5
weeks on the 6th week the mice were put down. Over the course of the experiment 2 mice
died in their cage unexpectedly (PST and Tamoxifen) and therefore the data presented is
based on results from the remaining mice.

3.3.1 Breast Cancer Tumors Successfully Generated In RAG 2M Mice
We attained a 100% success rate in the development of human breast cancer
tumors in each of the mice injected in the study. Figure 3-15 shows clearly visible
subcutaneous tumors. Due to the hair on the mice it was difficult to measure the
progression of tumor size over the course of treatment and so therefore only gross weight
measurements were recorded during the treatment phase of the experiment. A total of six
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weight measurements were taken over the course of the study as observed in figure 3-16
there were no significant changes in the gross weights of the mice. This data is
preliminary and needs to be repeated to generate accurate results.
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Figure 3-15: Tumorigenesis in RAG 2M Mouse Model

Figure 3-15: Tumorigenesis in RAG 2M mouse model established by the injection of 6 x 10 MCF-7
cells subcutaneously as per protocol.

Figure 3-16: Gross weight Measurements of Mice
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Figure 3-16: Gross weight measurements of mice. RAG 2M Mice were weighed 6 times over a 5 week
period as part of handling procedure to record the total weight of the mouse over the course of treatment.
Plotted is the weight of mice in the experimental groups which include: Placebo, PST, Tamoxifen (TAM)
and PST + TAM.
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3.3.2 TUNEL and DAPI Staining Reveal No Toxicity To Kidney and Liver
To evaluate genotoxicity of the treatments to organ tissue, the kidney and liver of
each mouse was removed and prepared in wax blocks at which point 8 micron sections
were prepared on slides as per protocol. Terminal Uridine Nick End Labeling assay was
carried out as mentioned in materials and methods in order to evaluate the integrity of
DNA. Each slide was also stained with DAPI to evaluate the nuclear morphology of the
cells. All results are preliminary and will require further testing to validate.
The liver of each mouse was analyzed and figure 3-17a shows that there was no
positive TUNEL staining for any of the treatment groups. The DAPI stains revealed that
the nuclear morphology of the tissues appeared consistently healthy across all test groups
(figure 3-17a).
The kidneys of each mouse were also removed and sectioned as per protocol to
check for potential genotoxicity. Figure 3-17b shows that no apparent genotoxic effects
were observed when analyzing the TUNEL stains qualitatively. The lack of TUNEL
staining in these tissues (figure 3-17b) directly indicates the lack of nicks in the nuclear
DNA which co-relates to the lack of genotoxicity in all samples analyzed. From
qualitative analysis of the DAPI stains in 3-17b it was revealed that the nuclear
morphology does not change between the 3 treatments (PST, Tamoxifen, and PST +
Tamoxifen) when compared to the placebo.
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3.3.3 TUNEL and DAPI Staining Reveal Toxicity to Treated Tumor Samples

From our preliminary data it was observed that tumor samples from the treated
groups (PST, Tamoxifen and PST + Tamoxifen) exhibited positive TUNEL labeling
when compared to placebo. As observed in figure 3-17c there appears to be TUNEL
DNA labeling particularly in the PST + Tamoxifen treated tumors (as denoted by bright
green fluorescence). There also seems to be a greater intensity of DAPI staining in the
PST + Tamoxfen treated tumors (figure 3-17c). TUNEL labeling was also observed to a
lesser extent in PST or Tamoxifen alone; however these observations are only
preliminary and more testing will be required to validate the findings.
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Figure 3-17a: TUNEL Labeling and DAPI Staining of Liver Tissue Samples
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Figure 3-17a: TUNEL labeling and DAPI staining of liver tissue samples. Liver sections for each
treatment group were stained by TUNEL and DAPI as per protocol to visualize apoptotic features. Bright
TUNEL staining indicated DNA nicks.

Figure 3-17b: TUNEL Labeling and DAPI Staining of Kidney Tissue Samples
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Figure 3-17b: TUNEL labeling and DAPI staining of kidney tissue samples. Kidney sections for each
treatment group were stained by TUNEL and DAPI as per protocol to visualize apoptotic features. Bright
TUNEL staining indicated DNA nicks.
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Figure 3-17c: TUNEL Labeling and DAPI Staining of Tumor Tissue Samples
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Figure 3-17c: TUNEL labeling and DAPI staining of Tumor tissue samples. Tumor sections for each
treatment group were stained by TUNEL and DAPI as per protocol to visualize apoptotic features. Bright
TUNEL staining indicated DNA nicks.
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3.3.4 Histological Analysis of Tissues Using Hemotoxalyn and Eosin

To analyze the overall morphology of the tissue samples, we analyzed the
sectioned liver, kidney and tumor samples using hematoxylin and eosin staining.
Hematoxalyin stains the nucleus and eosin stains the cytoplasm thus visualization of the
morphological features of a cell becomes possible. Proper histochemical analysis will
have to be performed by a trained pathologist these observations are only qualitative and
preliminary.
Figure 3-18a shows that the liver samples in all treatments appear to be relatively
same in consistency with respect to nuclear and cellular morphology. As observed in
figure 3-18a there does not appear to be any morphological changes when compared to
placebo. Furthermore, analysis of the kidney samples exhibited similar staining in all the
treatment samples studied (figure 3-18b). Therefore no severe liver and kidney cellular
changes were observed when comparing the treatment groups to placebo indicating
minimal effect towards treatment.
Tumor samples analyzed by hematoxalyn and eosin revealed interesting
morphological features in the different treatment groups. It was found that the density of
cells appeared to be higher in placebo and Tamoxifen groups (figure 3-18c). It is
observed that the morphology of the treatment groups, in particular the combined
treatment of PST + Tamoxifen, had drastic effects on the morphology of the cells (figure
3-18c). Tamoxifen + PST treated tumors exhibtit inconsistencies in nuclear shape and
cellular density (figure 3-18c). These insights are preliminary observations and the slides
must be properly analyzed by a trained pathologist.
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Figure 3-18a: Hematoxylin and Eosin Stain: Liver Morphology

Placebo

PST

Tamoxifen

PST + Tamoxifen

Figure 3-18a: Hematoxylin and eosin stain: liver morpholgy. Tissue morphology was analyzed by
staining the nucleus with eosin and the cytosol with hematoxylin. Pictures were taken at 200x
magnification using a phase-contrast light microscope and observed by motic imaging software.
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Figure 3-18b: Hematoxylin and Eosin Stain: Kidney Morphology

Placebo

PST

Tamoxifen

PST + Tamoxifen

Figure 3-18b: Hematoxylin and eosin stain: kidney morpholgy. Tissue morphology was analyzed by
staining the nucleus with eosin and the cytosol with hematoxylin. Pictures were taken at 200x
magnification using a phase-contrast light microscope and observed by motic imaging software.
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Figure 3-18c: Hematoxylin and Eosin Stain: Tumor Morphology

Placebo

PST

Tamoxifen

PST + Tamoxifen

Figure 3-18c: Hematoxylin and eosin stain: tumor morphology. Tissue morphology was analyzed by
staining the nucleus with eosin and the cytosol with hematoxylin. Pictures were taken at 200x
magnification using a phase-contrast light microscope and observed by motic imaging software.
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3.3.5 Western Blot Analysis: Kidney, Liver and Tumor Samples
To determine the expression and localization of key apoptotic factors, western
blot analysis was performed on flash frozen tissue samples from the in-vivo studies.
Tissue samples included liver, kidneys and tumor, of each mouse. The tissues were
homogenized and fractionated into nuclear, cytoplasmic and mitochondrial fractions (as
described in materials and methods). Western blot analysis was carried out with 50ug of
protein from cytosolic and mitochondrial fractions and the use of Bax, Bad, Cytochrome
c and actin antibodies allowed for qualitative comparisons of the levels of these proteins
in each tissue and fraction.
Liver samples were prepared into cytosolic and mitochondrial fractions and
probed for key apoptotic factors as mentioned previously. As shown in figure 3-19a no
changes in the levels of apoptotic factors (Bax, Bad and Cytochrome c) were observed in
the cytoplasmic fraction. Furthermore, figure 3-19b demonstrates that the mitochondrial
fractions did not exhibit any changes in the levels of Bax and Cytochrome c.
Kidney samples were then analyzed by western blot analysis, from figure 3-20a
shows that the cytosolic component did not have any drastic changes in the levels of Bax,
Bad, and Cytochrome c. As observed in figure 3-20b the kidney mitochondrial fraction
did not show significant changes in the level of Bax and Cytochrome c.
Tumor samples analyzed by western blot demonstrated interesting preliminary
results. In particular, figure 3-2la shows that the cytosolic fraction of tumor cells has an
increase in the level of Cytochrome c in the Tamoxifen and the PST + Tamoxifen treated
tissues. The pro-apoptotic Bad protein had increased levels in the cytosol of PST treated
tumors more so than any other treatment (figure 3-21a). Mitochondrial fractions prepared
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from tumor samples exhibit a distinct increase in the level of Bax protein in the PST +
Tamoxifen treated tumor (figure 3-21b).
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Figure 3-19a: Mouse Liver Cytosolic Fraction
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Figure 3-19a: Mouse liver cytosolic fraction. Liver tissue was homogenized and cytosolicfractionswere
isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel and
immunoblotted for Bad, Bax, Cyt c and Actin.

Figure 3-19b: Mouse Liver Mitochondrial Fraction
Placebo

PST

TAM

PST + TAM

Figure 3-19b: Mouse liver mitochondrial fraction. Liver tissue was homogenized and mitochondrial
fractions were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel
and immunoblotted for Bax and Cyt c.
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Figure 3-20a: Mouse Kidney Cytosolic Fraction
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Anti Actin->

Anti Cyt C -»

Anti Bax-»

Anti Bad->
Figure 3-20a: Mouse kidney cytosolic fraction. Kidney tissue was homogenized and cytosolic fractions
were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel and
immunoblotted for Bad, Bax, Cyt c and Actin.

Figure 3-20b: Mouse Kidney Mitochondrial Fraction
Placebo
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Anti Cyt C->
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Figure 3-20b: Mouse kidney mitochondrial fraction. Kidney tissue was homogenized and mitochondrial
fractions were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel
and immunoblotted for Bax and Cyt c.
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Figure 3-21a: Mouse Tumor Cytosolic fraction
Placebo

PST

TAM

PST + TAM

Figure 3-21a: Mouse tumor cytosolic fraction. Tumor tissue was homogenized and cytosolic fractions
were isolated as per protocol. Approximately 50ng of protein were loaded on polyachrylamide gel and
immunoblotted for Bad, Bax, Cyt c and Actin.

Figure 3-21b: Mouse Tumor Mitochondrial Fraction
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TAM

PST + TAM

Figure 3-21b: Mouse tumor mitochondrial fraction. Tumor tissue was homogenized and mitochondrial
fractions were isolated as per protocol. Approximately 50ug of protein were loaded on polyachrylamide gel
and immunoblotted for Bax and Cyt c.
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CHAPTER 4: DISCUSSION
The holy grail of anti-cancer therapy is selective elimination of cancer cells
without affecting normal tissues. In the present work we demonstrate that PST is very
selective and efficient in inducing apoptotic cell death in two different breast cancer cell
lines without affecting the non-cancerous cells. In addition, we observed that treatment
with low doses of Tamoxifen and PST had a synergistic effect in inducing apoptosis in
cancerous MCF-7 and Hs578-T cells. Furthermore our results suggest that both these
compounds may be inducing apoptosis by synergistically destabilizing mitochondria in
cancer cells selectively.

4.1 Synergy between PST and Tamoxifen is Estrogen Receptor Pathway
Independent
Tamoxifen, is a well established antagonist to estrogen receptor that primarily
induces apoptosis in ER positive breast cancer cells by modulation of gene expression.
Interestingly, recent research has indicated that besides ER-mediated genomic effects,
Tamoxifen induces mitochondrial destabilization and apoptosis in an ER- independent
manner in several ER negative cancer cell lines (Mandlekar, Kong 2001).
We used Tamoxifen in combination with PST to see if there is a synergistic
effect.

Indeed, our results using Hoechst staining clearly indicated that lower

concentrations of 0.5uM PST and 5uM Tamoxifen together induced apoptosis in higher
numbers than either compound alone in breast cancer MCF-7 cells.

At a period of 72

hours the apoptotic index of 0.5uJVI PST increased by approximately 20% when
incubated along with 5uM Tamoxifen. We validated this result by quantifying the
synergistic effect using flow cytometry and observed that annexin V binding gave similar
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synergistic profiles in the MCF-7 cells, were in which the apoptosis inducing potential of
PST at a low dose of 0.5 uM increased by 20% upon combined 5uM Tamoxifen
incubation. The TUNEL assay carried by flow cytometry revealed that 0.5 uM PST
exhibited a approximate 4% increase in apoptotic induction when combined with 5 uM
Tamoxifen, this is far less than the result obtained in the annexin-V result, however it can
be explained as DNA knicks are a later stage event in apoptosis, when cells undergo
membrane blebbing, however phosphatidyl serine flipping (as observed by annexin-V
binding) is an early stage apoptotic marker were cells are still in-tact. Therefore at 72
hours it is expected that most cells will exist in the later stage of apoptosis, in which
condensation of DNA, membrane blebbing and cell shrinking occurs (Duke et. al. 1996).
This therefore would pose challenges in the gating of these cells in the flow cytometry
machine. It would be interesting to look at these stains at earlier time points, however due
to access restrictions we were only able to gain accurate data for the 72 hour time period.
Our result show that the synergistic effect was also observed in ER negative
breast cancer cells (Hs578-T). This effect however was observed at higher Tamoxifen
concentrations. Specifically we found that the apoptotic index of 0.5uM PST was
increased by 20% when incubated in combination with lOuM Tamoxifen, where as
lOuM Tamoxifen treatment on its own did not induce any apoptosis in the Hs578-T cell
line. This result therefore demonstrated that the synergistic effect is ER independent and
potentially plays a role on mitochondria.

4.2 Role of Mitochondria in Synergistic Response
Differences between the mitochondria of cancerous versus normal cells have been
researched intensely (Don, Hogg 2004, Villa, Doglia 2004). As previously discussed,
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many cancerous cells have an altered metabolism, mitochondrial DNA mutations and
altered membrane compositions (Green, Kroemer 2004, Villa, Doglia 2004, ModicaNapolitano, Singh 2002, Polyak et. al. 1998).
Increases in the total whole cell ROS have been linked to destabilization of
mitochondria (Fluery et. al. 2002). We looked at total ROS production in both MCF-7
(ER+) and Hs578-T (ER-) cells. We found that the combined treatment of 0.5uM PST
and 5uM Tamoxifen induced greater total ROS then either compound separately in both
the ER+ MCF-7 (ER+) and Hs578-T (ER-) cells.
Depolarization of the mitochondrial membrane potential is essential for
mitochondrial induced apoptosis (Green, Kroemer 2004, Yuan et. al. 2001). We
confirmed this effect by JC-1 staining to observe the collapse of the mitochondrial
membrane potential upon PST and Tamoxifen treatment. It was found that the combined
treatment of PST and Tamoxifen reduced mitochondrial membrane potential in both
MCF-7 (ER+) and H-578-T (ER-) cells upon 48 hour treatment.
Previous work has indicated that PST has mitochondrial targets which allow for
selective induction of apoptosis (McLachlan et. al. 2005). Furthermore current research
indicates that Tamoxifen has the ability to induce apoptosis through mitochondrial
dysfunction, independently of its function as an estrogen receptor antagonist (Mandlekar,
Kong 2001, Moreire et. al. 2006). To verify if mitochondria are being affected by the
combined treatment of PST and Tamoxifen we performed ROS measurements directly on
isolated mitochondria. Mitochondria from MCF-7 (ER+) and Hs578-T (ER-) cells were
isolated and a HRP/Amplex Red ROS assay was carried out. Furthermore, we used
Paraquat as a positive control. Paraquat induces ROS by disruption of the electron
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transport chain (Mollace et. al. 2003). We found that the combined treatment of 0.5uM
PST and 5(J.M Tamoxifen induced mitochondrial ROS increases in greater amount then
either compound alone and to the same extent in both cell lines investigated. Indicating
that both compounds (Tamoxifen and PST) target specific regions of the mitochondria
and inducing increases in ROS production.
Mitochondrial membrane permeablization plays a key role in apoptosis by
releasing caspase activators such as Cytochrome c (Fernadez-Chenca 2003, Duchen
2004, Green, Reed 1998). We observed Cytochrome c leakage from isolated MCF-7
mitochondria. We found that a minimum of 1 uM PST was required to induce cytochrome
c leakage from isolated mitochondria. Intersestingly 0.5uM PST was found to be
insufficient to cause cytochrome C release, however when treated in combination with
5uM Tamoxifen we began to see mitochondrial Cytochrome c leakage. This result further
supported the previous observation that the mitochondria seem to be targets of both PST
and Tamoxifen in inducing destabilization of mitochondrial membrane leading to
apoptosis.

4.3 PST and Tamoxifen Treatment Does Not Induce Apoptosis In Normal Cells
The observations of synergy between PST and Tamoxifen on whole cells as well
as isolated mitochondria supports the hypothesis that vulnerability of cancer cell
mitochondria could be used as cancer specific target to induce apoptosis selectively in
cancer cells. However to verify the selectivity we chose to work with NHF cell model,
NHF cells were chosen because of the relative ease of use and maintenance, we
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encountered problems with contamination from company stocks of normal breast
fibroblast cells (Hs578-Bst).
Previous work with anticancer compounds has led to the discovery of many
clinically used chemotherapeutics which target cancerous cells non-selectivly and
therefore have drastic side-effects (Yeung et. al. 1999, Boos, Stopper 1999). PST has
been previously observed to exhibit little toxicity to normal cell lines (McLachlan et. al.
2005). We therefore tested the combined effect of PST and Tamoxifen on normal human
fibroblasts to evaluate any potential toxic effects.
From our analysis of Hoechst staining it was found that no clear indication was
observed of apoptotic induction in NHF cells at all concentrations of PST and Tamoxifen
studied. Observing the whole cell ROS we found that there was no apparent increase in
whole cell ROS when compared to control untreated NHF cells. Furthermore it was
found that upon treatment of isolated mitochondria from NHF cells we did not see any
significant increase in ROS production from control. Likewise JC-1 staining indicated
that the mitochondrial membrane potential in these cells remains in tacked even when
challenged at the high luM PST and lOuM Tamoxifen concentrations. Therefore we
observed that the synergistic effect is specific towards cancer cells.

4.4 Localization of Key Apoptotic Factors in PST Induced Apoptosis
The localization and expression of pro/anti-apoptotic proteins dictate whether a
cell undergoes apoptosis or survives. Some Bcl-2 proteins localize to different
compartments within the cell. During survival and cell proliferation, pro-apoptotic
proteins such as Bax are generally compartmentalized in the cytosol while the anti-
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apoptotic proteins such as Bcl-2 and Bcl-xl are found on the mitochondrial membrane
and endoplasmic reticulum (Kuwana, Newmeyer 2003). Upon encountering a stress
signal, the pro-apoptotic protein Bax will migrate to the outer mitochondrial membrane
and cause the dysfunction of mitochondrial membrane potential (Goping et. al. 1998).
One of the key stresses imposed on a cell that tips the balance between pro/anti-apoptotic
state is the level of reactive oxygen species present within the cell. It is thought that ROS
increases can be tolerated in cancer cells by the up-regulation of proteins such as Bcl-2
and Bcl-xl, which protect the mitochondria from mitochondrial membrane collapse
(Harris, Thompson 2000). However if the ROS condition inside a cell is too high then
apoptotic cell death is mediated by the up-regulation and activation of anti-apoptotic
proteins such as Bax, this in turn causes Bax to migrate to the mitochondrial membrane
were it is thought to interact with the protein transition pore complex (MPTP) and cause
mitochondrial apoptotic factors such as Cytochrome c to be released (Harris, Thompson
2000).
Here we found Bax localization to the mitochondria following PST treatment and
direct evidence for Cytochrome c leakage. In both MCF-7 and Hs578-T cells we found
localization of Bax protein to the mitochondria, as well as Cytochrome c leakage after 48
hours of luM PST treatment. This may be attributed to increases in reactive oxygen
species caused by direct PST interaction with mitochondria. Interestingly, we found that
levels of Bad protein were increased in the treated cytosolic fraction of both cell lines.
This result is particularly interesting because it suggests that there is up-regulation of Bad
protein expression in both cell lines since Bad does not have a mitochondrial binding
domain and predominantly resides in the cytosol. Bad protein acts by sequestering and in-
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activating Bcl-2 protein (Kuwana, Newmeyer 2003). When looking at the relative levels
of pro/anti-apoptotic proteins in the normal NHF cell line we did not see any significant
differences in any of the protein levels. Due to the previous result that PST can directly
cause release of Cytochrome c at concentrations of 1 uM we therefore reason that PST
both increases levels of ROS leading to apoptotic susceptibility as well as directly
permeabilizing the mitochondrial membrane.
In future studies it should be noted that both Actin and Succinate Dehydrogenase
controls should be run in both treated and control samples to give a reflection of relative
purity in the sample.
Caspases are apoptotic messengers; their role is to propagate the apoptotic signal
towards a state of cell suicide. Caspase-8 activation indicates extrinsic apoptotic signaling
when occurring at early time points (Plesnila et. al. 2001). Using a cell membrane
permeable caspase-8 substrate we found that late activation of caspase-8 occurs in both
Hs578-T (48 hour) and MCF-7 (24 hour) cells indicating that caspase-8 activation occurs
in a later stage of apoptosis induction. The difference in time of activation of caspase-8,
we reason, is due to the fact that MCF-7 cells are caspase-3 deficient (Essmann et. al.
2004), and therefore a greater reliance on caspase-8 and other apoptogenic factors is
required to bi-pass caspase-3 induced apoptosis in MCF-7 cells.

4.5 MCF-7 Cells Do Not Become Resistant to PST Treatment
Resistance to treatment is a major obstacle in chemotherapeutic development and
research. Cancer cells have the capacity to up-regulate ATP-binding cassette transporter
(ABC transporters) genes which give it the ability to reduce the amount of xenobiotics
(drugs, toxins), as well as endobiotics within the cell and therefore reduce the effect of a
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specific drug (Trock et. al. 1997). Therefore, to observe any resistance of MCF-7 cells to
PST treatment we exposed these cells to prolonged sub-lethal dose of 25nM or 50nM
PST for a period of 20 days, we did not observe any changes in the sensitivity of MCF-7
cells to the lethal dose of luM PST treatment. This result indicates that PST does not
induce mechanisms of resistance in MCF-7 cells.

4.6 In-vivo Study of PST and Tamoxifen Synergy
Previous athymic nude mouse models that were used to establish colon tumors
would not allow for MCF-7 tumorigenisis. We used a mouse model for breast cancer
consisting recombinase deficient RAG 2M mice as described by Webb et. al. 2007. Each
mouse had to be injected with a slow release 60-day 17-|3 estradiol tablet 24 hours prior
to cancer cell injection. Approximately 6 X 106 human breast cancer (MCF-7) cells were
injected in the right hind flank. We were successful in establishing tumors in all the mice
in our study and injected them with PST or Tamoxifen accordingly. At this point all data
is preliminary since the experimental procedure had to be standardized for these mice.
Specific problems were encountered over the course of the experiment. For
instance these mice contained fur making it difficult to measure tumor size progression
using calipers. Also, over the course of the experiment two of the mice died in their cage
(one PST and one Tamoxifen), therefore reducing the number of mice in the experiment.
Tamoxifen was prepared in peanut oil as described previously (Paine-Murrieta et. al.
1997) because it is lipid soluble. However, this method of administering Tamoxifen gave
rise to complications with respect to absorption. When dissecting the mice, oil pockets
were found in the subcutaneous portions indicating that the oil had not properly absorbed
into the body. Furthermore, growth rates of the tumors varied: some mice exhibited
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tumors before others; the mice were treated accordingly to when tumor sizes reached
approximately 5mm in diameter. Therefore, these preliminary results must be repeated
with a larger sample of mice in order to make the findings statistically significant.
Despite complications, certain changes to the protocol are proposed here to
enhance the reproducibility of the experiment. Nude mice were not used for modeling
breast cancer because it is notoriously difficult to establish hormone dependent tumors
through subcutaneous injections (Giovanella, Fogh 1985). RAG 2M mice were used
because injected MCF-7 cells were reported to establish into tumors (Webb et. al. 2007).
However, It has been reported that the use of matrigel greatly increases the
tumorigenecity of MCF-7 cells in nude athymic mice (Fridman et. al. 1991). Therefore an
alternate approach would be to use matrigel to establish MCF-7 tumors, which are
relatively same size prior to insertion into immunocompromised mice. This model would
have the advantage of increasing the ability to monitor tumor progression over the course
of treatment, since the tumors would be relatively the same size and clearly visible.
Work by Yue et. el 1994. showed that once injected into the subcutaneous cavity,
MCF-7 cells transfected with human placental aromatase gene (MCF-7a) provide a nonovarian source of estrogen in nude BALB/c athymic mice. Furthermore, this work
showed that these transfected cells (MCF-7a) developed into tumors rapidly and
consistently when mice were given androstenedion (aromatase substrate) at a
concentration of O.lmg/per mouse/per day (injected subcutaneously) when compared
with mice transfected with a control vector (MCF-7c). Therefore these considerations
could be taken into account when developing future mouse models in our in-vivo study to
establish more accurate and reliable data.
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CHAPTER 5: FUTURE PERSPECTIVES

Critical hurdles exist in the research of PST as an anticancer compound. One of
the major obstacles is the development of a synthetic compound produced by an organic
process. Our collaborator Dr. McNaulty, an organic chemist at McMaster University is
currently working on ways to simplify the organic synthesis of PST and has successfully
developed structural analogues of PST, which help to deduce

the minimum

pharmacophore required for activity (McNulty et. al 2005). It is possible that an active
derivative of PST may retain synergistic properties, and when combined ^with Tamoxifen
may be used to treat a variety of cancer types.
The development of a synthetic PST derivative will allow for tritium or carbon-14
labeling. Radioactive labeling will allow us to therefore pinpoint the exact biochemical
target of PST, and therefore expand our knowledge in cancer cell susceptibility.
The ability of Tamoxifen to destabilize the mitochondria enables testing of
combinatorial treatment (PST and Tamoxifen) in a variety of cell lines, not just breast
carcinoma. Currently, exactly that is being applied to a human melanoma cell line, and in
the future, we will investigate the synergistic response in a host of different cancer cells
(ex. Lymphoma, Colon, Pancreatic, Prostate, Lung...etc.) in order to observe any
relevant increases in the apoptotic index of combined treatment versus single treatment
alone.
Changes in protein expression and localization caused by PST treatment can be
further investigated by 2-dimensional in gel electrophoresis (2-DIGE). Control and
treated cellular fractions (cytosolic and mitochondrial) can be fluorescently labeled with
separate dyes which incorporate into either lyseine or cysteine residues and give two
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distinct colors green or red. The fractions can then be run together on the same 2dimensional gel and the relative intensity of each spot, with respect to their color, can
determine the relative amount of up-regulation or down-regulation of the proteins in
specified cellular fractions (mitochondrial and cytosolic).
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CHAPTER 6: Conclusions
We have clearly demonstrated the apoptosis-inducing activity of PST in breast
cancer cells, with no detectable toxicity to non-cancerous cells. The intrinsic pathway of
apoptosis was observed by mitochondrial destabilization through ROS increases and
Cytochrome c release in both Hs578-T and MCF-7 breast cancer cell lines, without any
indication of this occurrence in the normal counterpart NHF cell line. Interestingly, there
was a synergistic apoptotic effect with combined treatment of PST and Tamoxifen in
both estrogen receptor positive (MCF-7) and estrogen receptor negative (HS578-T) cell
lines. More importantly it was established that both of these drugs target cancer cell
mitochondria selectively indicating that the observed effect is independent of estrogen
receptor. Furthermore, we developed for the first time in our lab, a human breast cancer
(MCF-7) mouse model using RAG 2M mice, although the results are inconclusive, they
do open the window for future experiments on the synergistic response of PST and
Tamoxifen in-vivo. Therefore a new window of opportunity has now been opened to
develop novel combination therapy for cancer treatment.
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